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Transforming growth factor β (TGF-β) superfamily signaling pathways are ubiquitous and essential regulators of cellular processes including
proliferation, differentiation, migration, and survival, as well as physiological processes, including embryonic development, angiogenesis, and
wound healing. Alterations in these pathways, including either germ-line or somatic mutations or alterations in the expression of members of these
signaling pathways often result in human disease. Appropriate regulation of these pathways is required at all levels, particularly at the ligand level,
with either a deficiency or an excess of specific TGF-β superfamily ligands resulting in human disease. TGF-β superfamily ligands and members
of these TGF-β superfamily signaling pathways also have emerging roles as diagnostic, prognostic or predictive markers for human disease.
Ongoing studies will enable targeting of TGF-β superfamily signaling pathways for the chemoprevention and treatment of human disease.
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During embryonic development human cells are organized
into a complex network of tissues, organs, and systems that
carry out the normal physiological processes of life. Home-
ostasis, both during development and in the adult, is achieved
through a careful balance of signaling pathways which transmit
signals through ligands circulating through the body and
through cell surface receptors and their downstream signaling
pathways. Most human diseases arise from either inappropriate
activation or inhibition of these signaling pathways. One of the
most ubiquitous regulators of embryonic development, physio-
logical, and cellular processes is the transforming growth factor
β (TGF-β) superfamily of cytokines.⁎ Corresponding author. 354B LSRC, Research Drive, Box 91004, Durham,
NC 27708, USA. Tel.: +1 919 668 1352; fax: +1 919 681 6906.
E-mail address: blobe001@mc.duke.edu (G.C. Blobe).
0925-4439/$ - see front matter © 2008 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2008.01.006The TGF-β superfamily of cytokines contains more than 30
structurally related polypeptide growth factors including TGF-
βs (1–3), activins (A, B), inhibins (A, B), bone morphoge-
netic proteins (BMPs 1–20), growth differentiation factors
including myostatin, nodal, leftys (1,2), and Müllerian-
inhibiting substance (MIS) [1–3]. The TGF-β superfamily
members share a conserved cysteine knot structure, and are
ubiquitously expressed, with nearly every cell in the human
body expressing and responding to at least one member of this
superfamily [4]. The TGF-β superfamily normally functions to
regulate embryonic development and cellular homeostasis,
including regulation of proliferation, differentiation, apoptosis,
and extracellular matrix remodeling in a cell and context
specific manner [3–7].
Alterations in TGF-β superfamily pathways, including either
germ-line or somatic mutations or alterations in the expression
of members of these signaling pathways often results in human
disease, including developmental disorders, vascular diseases,
and cancer [8,9]. Here we review the role of TGF-β superfamily
signaling pathways in human diseases including the role in
hereditary diseases, and conclude with assessing the potential
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predictive biomarkers, or as targets for the prevention or treat-
ment of human disease.
1.1. TGF-β superfamily signaling
Mechanisms of TGF-β superfamily signaling have been the
focus of several excellent recent reviews [2,3,5,10–12]. Briefly,
TGF-β superfamily ligands initiate their cellular effects by
binding to high affinity cell surface receptors, including type I
(activin like kinase (ALK) 1–7) and type II TGF-β superfamily
receptors, which together comprise the only known family of
serine/threonine kinase receptors (Table 1, Fig. 1). In addition,
there are a growing number of TGF-β superfamily co-receptors,
receptors that bind ligand and regulate ligand binding to and
signaling through their corresponding signaling receptors, but
have been traditionally thought not to signal directly (Table 1,
[13]). The type II receptors are constitutively active serine/
threonine kinases, with ligand binding resulting in conforma-
tional changes that induces recruitment and complex formation
with an appropriate type I receptor (Table 1, [9,12–14], Fig. 1).
The type II receptor then phosphorylates the type I receptor in
the GS domain (glycine serine rich) immediately amino-terminal
to the kinase domain, activating its serine/threonine kinase
activity [1,3,6,12]. The activated type I receptors mediate their
cellular effects through interaction and phosphorylation of Smad
proteins, a family of conserved transcription factors. The recep-
tor Smads (R-Smads) are directly phosphorylated by the type I
receptors (Table 1, Fig. 1). Upon phosphorylation, two activated
R-Smads form a complex with the common Smad, Smad4, and
this complex accumulates in the nucleus, where it can interact
with various transcription factors, co-activators or co-repressors
to modulate the expression of a multitude of genes (Fig. 1
[1,10]).
TGF-β superfamily co-receptors, like other signaling co-
receptors, regulate and contribute to TGF-β superfamily signaling
through a variety of mechanisms. Although originally defined for
their role in either conferring or enhancing ligand binding to the
signaling receptors, recent studies support additional roles for
these co-receptors in: (1) establishing morphogen gradients
during embryonic development; (2) antagonizing ligand function
by shedding their extracellular domains into the extracellular
space; (3) regulating receptor localization and internalization;
(4) regulating cellular adhesion; and (5) orchestrating signaling
[13]. For example, the TGF-β superfamily co-receptor, TβRIII
(or betaglycan), regulates the function of inhibin [15–17], BMP
[18], and TGF-β ligands [19–21] through binding to these
ligands, mediating the interaction of these ligands with other
TGF-β superfamily receptors (through the action of both cell
surface and soluble TβRIII) [19,20], and regulating the trafficking
and localization of these receptors [21]. Established ligands and
binding partners for specific TGF-β superfamily co-receptors are
listed in Table 1.
TGF-β superfamily signaling is not limited to Smad-mediated
pathways, as they can also mediate signaling responses through
non-Smad pathways, in particular the mitogen activated protein
kinase (MAPK) pathways, including extracellular-signal-regu-lated kinase (ERK), p38, and Jun N-terminal kinase (JNK); the
phosphoinositide 3-kinase (PI(3)K)/Akt pathway, and the NF-κB
pathway (Fig. 1 [2,10,22]). The precise mechanism by which
TGF-β superfamily ligands activate these pathways has not been
fully established [10]; however, progress is being made. For
example, recent studies have defined a novel interaction of beta3
integrins with the type II TGF-β receptor (TβRII), resulting in
Src-mediated phosphorylation of Y284 on TβRII, recruitment of
Grb2, and subsequent downstream activation of p38 [23–25].
TGF-β superfamily signaling pathways also crosstalk extensively
with many signaling pathways including the MAPK, PI(3)K/Akt
and tyrosine kinase receptor-mediated pathways (Fig. 1 [2,26]).
TGF-β superfamily signaling is regulated at all levels, begin-
ning at the ligand level. TGF-β1 is synthesized and secreted into
the extracellular matrix as an inactive precursor protein consisting
of a signal peptide, the latency associated peptide (LAP) domain,
and mature TGF-β1. Activation of TGF-β1 is thought to involve
proteolytic cleavage of LAP [27]. This cleavage is induced by
acidic environmental conditions, or executed by extracellular
proteases including thrombospondin-1 [28], plasmin, cathepsin D
[29], matrix-metalloproteinases 2 and 9 [30], and furin convertase
[31]. There is also evidence that integrins are involved in acti-
vating TGF-β in the absence of proteolytic cleavage. The LAP
domain of TGF-β has a RGD sequence that mediates binding to
integrins, and alphavbeta6 integrin was demonstrated to activate
TGF-β1 [32], and alphavbeta8 was shown to activate TGF-β1 via
anMT1-MMPdependentmechanism [33]. Unlike TGF-β, BMPs
are secreted in their active form. Their activity is regulated by
BMP antagonists, proteins that bind directly to BMPs and prevent
them from interacting with their respective type I and type II
receptors (Fig. 1 [34]). There are three subfamilies of BMP
antagonists based on the size of their cysteine knot; (1) CAN,
(2) twisted gastrulation, and (3) the chordin/noggin families [35].
These BMP antagonists have differential affinities for BMPs. For
example, Sclerostin binds to BMP-6 and BMP-7 with high
affinity and toBMP-2 andBMP-4with low affinity [36]; whereas,
noggin binds to BMP-2 and BMP-4 with high affinity and to
BMP-7 with low affinity [34]. These BMP antagonists also have
differential expression patterns, localizing their effects to specific
tissues [34]. The importance of these antagonists in regulat-
ing BMP signaling during development is evident from the
phenotypes of the knock-out mice. noggin(NOG)/chordin double
knock-out mice display severe craniofacial malformations [37]
and in single NOG knock-outs, growth plates are enlarged and
joint initiation is disrupted [38].
TGF-β superfamily signaling is also regulated at the levels of
the receptors, with FK506-binding protein 12 (FKBP12)
binding the GS domain of the type I superfamily receptors,
preventing phosphorylation by their respective type II receptors,
and maintaining the type I receptor in an inactive conformation
[39,40]. Localization and trafficking of the signaling receptors
are also important for regulating TGF-β signaling. Smad anchor
for receptor activation (SARA), which links receptors and
Smads and is localized on the plasma membrane and early
endosomes, has been linked to an increase in TGF-β signaling
following clathrin-mediated endocytosis of the receptors [41].
In contrast, lipid raft or caveolin-mediated endocytosis results in
Table 1
TGF-β Superfamily Signaling Components
Receptor gene/protein Ligands, binding partners Receptor Smads
Type I receptors ACVRL1/ALK1 Activin A, BMP-9, TGF-β1, TGF-β3 1, 5, 8
ACVR1/ALK2 Activin A, BMP-6, BMP-7, MIS, TGF-β1, TGF-β2, TGF-β3 1, 5, 8
BMPR1A/ALK3(BMPRIa) BMP-2, BMP-4, BMP-6, BMP-7 1, 5, 8
ACVR1B/ALK4 Activin A, GDF-1, GDF-11, Nodal 2, 3
TGFBR1/ALK5(TβRI) TGF-β1, TGF-β2, TGF-β3 2, 3
BMPR1B/ALK6(BMPRIb) BMP-2, BMP-4, BMP-6, BMP-7, GDF-5, GDF-6, GDF-9b, MIS 1, 5, 8
ACVR1C/ALK7 Nodal 2, 3
Type II receptors ACVR2/ActRII Activin A, BMP-2, BMP-6, BMP-7, GDF-1, GDF-5, GDF-8, GDF-9b, GDF-11,
Inhibin A, Inhibin B
ACVR2B/ActRIIb Activin A, BMP-2, BMP-6, BMP-7, GDF-5, GDF-8, GDF-11, Inhibin A, Inhibin B, Nodal
BMPR2/BMPRII BMP-2, BMP-4, BMP-6, BMP-7, GDF-5, GDF-6, GDF-9b
AMHR2/MISRII MIS
TGFBR2/TβRII TGF-β1, TGF-β2, TGF-β3
Co-receptors TGFBR3/TβRIII Inhibin, TGF-β1, TGF-β2, TGF-β3, BMP-2, BMP-4, BMP-7, GDF-5
ENG/Endoglin In conjunction with appropriate type II receptor; Activin A, BMP-2, BMP-7, TGF-β1, TGF-β3
CRIPTO/Cripto GDF-1, GDF-3, Nodal, TGF-β1
RGMA/RGMa BMP-2, BMP-4
RGMB/RGMb(DRAGON) BMP-2, BMP-4
HJV/Hemojuvelin(RGMc) BMP-2, BMP-4
Pseudo-receptor BAMBI/BAMBI Associates with Type I receptors
Ligand antagonists CHRD/Chordin BMP-2, BMP-4
FST/Follistatin Activin A, Activin B, Inhibin
LEFTY1/Lefty1 Binds to Cripto, competes with Nodal
NOG/Noggin BMP-2, BMP-4, BMP-7
SOST/Sclerostin BMP-2, BMP-4, BMP-6, BMP-7
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have demonstrated that the TGF-β superfamily co-receptors,
TβRIII (or betaglycan) and endoglin regulate the cell surface
localization, internalization, and signaling of their respective
signaling receptors through interactions with the scaffolding
proteins, GAIP-interacting protein C-terminus (GIPC) [42] and
β-arrestin2 [21,43].
At the Smad level, Smad2/3 binding to SARA retains them in
the cytoplasm awaiting activation by C-terminal phosphorylation
by their respective type I receptor [44]. The ability of phos-
phorylated Smads to interact with Smad4 is also regulated, as the
ErbB2/Her2-interacting protein (Erbin) functions to sequester
Smad2/3 in the cytoplasm away from Smad4, thus preventing
TGF-β signaling [45]. In addition, de-phosphorylation of nuclear
accumulated Smads results in export back to the cytoplasm to
terminate signaling [46].
Once the pathway is activated, a number of feedback mecha-
nisms are turned on to regulate the duration of signaling. For
example, the inhibitory Smads (I-Smads), Smad6 and Smad7,
which lack the MH1 domain and whose production is directly
increased by both TGF-β and BMP signaling, inhibit TGF-β
superfamily signaling by competingwith R-Smads for association
with their respective type I receptors [47–50]. They also recruit
the E3 ubiquitin ligases Smad ubiquitin-related factor-1 (Smurf1)
and Smurf2, which ubiquitinate the Smads and type I receptors
resulting in protein degradation and termination of signaling
[51,52]. In addition, TGF-β superfamily signaling pathways also
stimulate the production of secreted proteins, which function to
both mediate and regulate signaling. For example, TGF-β
increases the production of secreted protein acidic rich in cysteine
(SPARC), which enhances TGF-β signaling [53]; cystatin C,which inhibits TGF-β signaling [54,55], and fibulin-5 [56], which
mediates TGF-β's effects on inhibiting VEGF signaling and
angiogenesis [57,58]. These data indicate that modification to
components of the TGF-β signaling cascade regulates their avail-
ability for signaling and ensures proper cellular responses. A sum-
mary of the TGF-β superfamily signaling pathways is presented in
Fig. 1.
Taken together, the complexity of TGF-β superfamily sig-
naling and regulation of these signaling pathways permits this
superfamily to elicit diverse and context-dependent cellular
functions to regulate normal homeostasis. Not surprisingly,
misregulation of TGF-β superfamily signaling pathways often
results in human disease [8].
2. Cardiovascular disease
TGF-β superfamily members critically regulate many differ-
ent processes within the cardiovascular system (CVS), includ-
ing cardiac development and angiogenesis. The predominant
TGF-β superfamily ligands expressed in the CVS are TGF-β1,
TGF-β2, TGF-β3, BMP-2, BMP-4, BMP-6, and BMP-7 [59].
The importance of the TGF-β superfamily in cardiovascular
development is evident from the significant phenotypes of knock-
out mice: (1) TGFB1−/− mice are embryonic lethal due to an
excessive systemic inflammatory response with massive infiltra-
tion of macrophages and lymphocytes into the heart and lungs
[60]; (2) TGFB2−/− mice are embryonic lethal due in part to
ventricular septum defects (VSD), myocardial thinning, and a
double outlet right ventricle (DORV) [61]; (3) TGFBR3−/− mice
are embryonic lethal, exhibiting cardiac defects similar to the
TGFB2−/− mice, with a failure of coronary vessel development
Fig. 1. TGF-β superfamily signaling pathways. TGF-β superfamily ligands in the extracellular space bind to their respective type II and type I receptors. This binding
is facilitated by the presence of co-receptors, including TβRIII. Within the extracellular space, there are negative regulators, including BMP antagonists, which bind to
TGF-β superfamily ligands and prevent them from binding to their respective cell surface receptors. When a TGF-β superfamily ligand binds its specific receptor
complex, a signal transduction cascade is initiated. The type I receptor's kinase domain becomes activated via phosphorylation by an appropriate type II receptor,
enabling the type I receptor to interact with and phosphorylate the Smad transcription factors. There are two classes of receptor Smads; the BMP responsive Smads,
which include Smad1, 5, and 8, and the TGF-β responsive Smads, which include Smad2 and 3. When these receptor Smads are phosphorylated, they form a trimeric
complex with the common Smad4 and this complex accumulates in the nucleus. Within the nucleus, the Smads interact with other transcription factors to affect the
transcriptome, resulting in regulation of cellular responses including growth, motility, and apoptosis.
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the myocardium of atrioventricular cushions results in valve
malformations [64], while deletion in the endothelium reduces the
formation of mesenchyme through reduced epithelial to
mesenchymal transition (EMT) and mesenchymal cell survival,
resulting in defective cardiac valve and septa formation [65];
and (5) specific knock-out of SMAD4 in the heart results in
hypocellular myocardial wall defects contributing to heart failure
[66].While a recent review focused on the extracellular regulationof TGF-β signaling and its effects on vascular development and
disease [67], here we will discuss the contribution of TGF-β
superfamily members to specific cardiovascular diseases.
2.1. Hereditary Hemorrhagic Telangiectasia
(Rendu–Osler–Weber syndrome)
Hereditary Hemorrhagic Telangiectasia (HHT) is an autosomal
dominant disease with variable penetrance in which vascular
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tions [68]. Clinically, these patients present as young adults and
onward with telangiectases of the skin, spontaneous recurrent
epistaxis, gastrointestinal bleeding, high cardiac output heart
failure, or neurological sequelae due to arteriovenous malforma-
tions [68,69]. There are two forms of HHT, HHT1 and HHT2,
which are often difficult to differentiate clinically; however, HHT1
is associated with a higher incidence of pulmonary, hepatic, and
cerebral arteriovenous malformations and HHT2 has a later
onset, lower penetrance, and is associated with more severe liver
involvement [68–70].
Genetic linkage studies of families with HHT identified
disease causing mutations in two TGF-β superfamily family
receptors, the co-receptor endoglin for HHT1 [71], and the
type I receptor ALK1 for HHT2 [72], that together account for
approximately 80% of HHT patients. Most of the mutations
identified in ENG and ACVRL1 in HHT patients are thought to
inactivate the receptors. In HHT1, 155 unique mutations in
ENG, all in the extracellular domain, have been identified [69].
Most of these mutations result in a truncated or mutated protein
that does not reach the cell surface [69]. In HHT1, 123 unique
mutations in ACVRL1 have been identified, and more than 50%
of these are missense mutations [69]. In contrast to endoglin,
these mutations span the extracellular, transmembrane, and
cytoplasmic domains of ALK1, with the majority affecting the
cytoplasmic domain. Protein modeling studies predict that the
majority of these mutations would affect protein folding and
stability. In both cases, HHT patients are heterozygous for these
disease causing alleles, suggesting a haploinsufficiency model
of disease pathogenesis [73].
Genetic analysis of ACVRL1 in a large HHT2 family estab-
lished that 58% of the offspring from two heterozygous indi-
viduals died in utero or shortly after death, while all of the
surviving offspring were heterozygotes [74]. This analysis sug-
gests that ALK1 is essential for embryonic development and
viability, as has been confirmed in murine models [75,76].
Other genes that contribute to HHT have been identified,
including mutations in the carboxy terminus of Smad4, with
resulting patients exhibiting a combined syndrome of Juvenile
polyposis ([73], see section on Juvenile polyposis) and HHT;
and an unidentified locus on chromosome 5 has been linked to
HHT patients without mutations in ENG, ACVRL1, or SMAD4
[77]. Whether mutations in SMAD4 and/or an unidentified gene
on chromosome 5 accounts for the 20% of remaining cases of
HHT remains to be elucidated [69]. In addition, a subset of
HHT2 patients also have Primary pulmonary hypertension ([78],
see section on Primary pulmonary hypertension), suggesting
that disruption of ALK1 signaling may also contribute to this
human disease.
The vascular dysplasias present in patients with HHT are
thought to form fromdilation of post-capillary venules and consist
of a dilated vessel with a single layer of endothelium attached to a
continuous basement membrane. HHT is thought to arise through
defective function of endoglin andALK1 in endothelial cells. The
importance of endoglin and ALK1 in endothelial cell function is
evident from the phenotypes of the ENG and ACVRL1 knock-out
mice. ENG−/− mice die at embryonic day 10.5 due to defects inangiogenesis, including failure to develop blood vessels in the
yolk sac, and severe cardiac defects [71]. ACVRL1−/− mice
also die at embryonic day 10.5–11.5 due to severe vascular
abnormalities, including hyperfusion and hyperdilation of blood
vessels, and impaired placental development [76,79]. Supporting
a haploinsufficiency model for HHT; ENG heterozygous mice
exhibit symptoms of HHT1 [80], and mice heterozygous for
ACVRL1 exhibit HHT2 symptoms including vascular lesions,
gastrointestinal bleeding, and hyperfusion and hyperdilation of
arterial and venous capillaries [81].
While the mutations of ENG and ACVRL1 in HHT and the
phenotypes of the knock-out mice support an important role for
these TGF-β superfamily receptors in endothelial cell biology and
angiogenesis, the mechanisms by which these receptors normally
function and how disruption of this signaling contributes to the
disease pathology is still being explored. Moreover, insight into
these processes has been hampered by several layers of
complexity in TGF-β superfamily signaling in endothelial cells.
First, in endothelial cells, TGF-β signals not only through the
ALK5/Smad2/3 pathway (as in most other cell types), but also
through ALK1/Smad1/5/8 [82]. These pathways have opposing
effects on endothelial cell proliferation andmigration; although, it
remains controversial which pathway inhibits and which pathway
stimulates these processes [82,83]. ALK1 and ALK5 signaling is
also not mutually exclusive, as ALK5 has been reported to be
required for ALK1 signaling [59,82]. The presence of these two
signaling pathways with divergent effects might provide a mech-
anism for the dose dependent, dichotomous function of TGF-β on
endothelial cells, promoting proliferation and migration at low
concentrations while inhibiting these responses at higher ligand
concentrations [82]. In any case, the effects of endoglin and
ALK1 on TGF-β signaling appears to be important as primary
endothelial cells isolated from HHT1 and HHT2 patients exhibit
reduced TGF-β-mediated transcription of Smad1 and Smad2/3
responsive promoters [84]. The precise mechanism and role of
ALK1 and ALK5-mediated TGF-β signaling in endothelial cells
is still being defined. Second, the role of endoglin in regulating
TGF-β superfamily signaling in endothelial cells appears to be
multifaceted. Unlike many other co-receptors, endoglin does not
bind ligand independently; thus, it is unlikely to present ligand
[85]. However, endoglin does bind several TGF-β superfamily
ligands, including TGF-β1, TGF-β3, activin, BMP-2 and BMP-
7, in conjunction with their respective binding receptors [85]. As
mutation in SMAD4, which is downstream of all TGF-β
superfamily ligands, also results in an HHT phenotype, and
BMP-9 has been identified as a bona fide ligand for ALK1 [86],
which or whether all TGF-β superfamily signaling pathways are
responsible for the disease pathology in HHT patients remains
unknown. In terms of effects on signaling, endoglin has been
reported to both increase and decrease, or have no effect onALK1
and ALK5 signaling, depending on the methods and model
systems used. Endoglin also has defined functions in inhibiting
migration through direct interactions of its cytoplasmic domain
with zyxin [87] and zyxin related protein-1 [88], which affects
focal adhesion complex assembly. Endoglin can also regulate
cyclooxygenase-2 production and activity to control synthesis of
prostaglandins (vasodilators), and can stimulate production of the
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demonstrated to antagonize TGF-β-mediated ERK signaling in
endothelial cells to inhibit endothelial cell migration [43].
Endoglin is also phosphorylated on its cytoplasmic domain by
ALK1, ALK5, and TβRII [90,91]. The functional consequences
of endoglin phosphorylation are still being defined. Third,
endoglin and ALK1 expression appears to be broader than
initially thought, with expression in vascular smooth muscle cells
and fibroblasts, suggesting that these compartments could
mediate an effect on HHT disease pathology as well [82,92,93].
Finally, ALK1 might signal through different pathways. For
example, decreasing ALK1 levels in microvascular endothelial
cells resulted in decreased migration mediated by JNK and ERK
[94], and interactions of ALK1with the nuclear receptor, LXR-β,
to inhibit ALK1 signaling have been reported [95]. Clearly,
further investigation is required to fully define the role of this
superfamily signaling pathway in the disease pathology of HHT.
2.2. Diseases of the aorta: Loeys–Dietz syndrome, Familial
thoracic aortic aneurysm syndrome, and arterial
tortuosity syndrome
Loeys–Dietz syndrome is an autosomal dominant aortic
aneurysm syndrome with affected patients having widely spaced
eyes, cleft palate, andwidespread vascular dilation placing them at
very high risk for aortic dissection or rupture [96]. Based on
an emerging role for the TGF-β signaling pathway in aortic
dissections associated with Marfan syndrome (see section on
Marfan syndrome), sequencing of TGFBR1 and TGFBR2 in
52 families with a history of Loeys–Dietz syndrome identified
disease causing somatic mutations in TGFBR2 and TGFBR1; 29
mutations were identified in TGFBR2, and 13 were identified in
TGFBR1. The majority of mutations identified were either adja-
cent to orwithin the serine/threonine kinase domains of TβRII and
TβRI. There were no phenotypic differences between those
patients that had TGFBR1 versus TGFBR2 mutations. These
receptor mutations identified were specific to this syndrome, as
unrelated patients with aortic aneurysms did not exhibit these
genetic alterations [96].While these mutationswould be predicted
to result in loss of function, experimentally, patients with these
mutations paradoxically have increased TGF−β signaling in
their aortic walls, suggesting that these mutations are either gain
of function, or that compensatory mechanisms overcome these
mutations [96].
Familial thoracic aortic aneurysm syndrome (TADD) is an
autosomal dominant disease that predisposes patients to progres-
sive enlargement of aorta aneurysms that can result in type
A aortic dissection, tearing of the arterial wall, and leakage of
blood into the layers of the vessel wall [97]. This is a life
threatening condition as aortic dissection often results inmassive
blood loss. TADD is the major cardiovascular complication of
Marfan syndrome, a hereditary connective tissue disorder (see
Marfan syndrome section). 19% of TADD patients that do not
have Marfan syndrome have affected first degree relatives,
suggesting that there is a common genetic contributor. Germ-line
mutations in TGFBR2 have been identified in patients with
TADD, including mutation of a conserved arginine to a cysteinewithin the kinase domain of the receptor [97], missense muta-
tions of highly conserved nucleotide bases within the kinase
domain, and a missense mutation downstream of the kinase
domain [98]. In addition, a missense mutation in the cytoplasmic
domain of TGFBR1 has been identified in patients with TADD
[98]. Protein structural modeling predicts that all of these TADD
associated receptor mutations would affect the ability of
receptors to transduce signals through their kinase domain [98].
Arterial tortuosity syndrome (ATS) is characterized by
vascular and skeletal manifestations that overlap with Loeys–
Dietz syndrome, including generalized tortuosity and elongation
of all major arteries, including the aorta, and hyperextensibility
and laxity of the skin and joints [99]. Patients with ATS have loss
of function mutations in the glucose transporter, GLUT10, which
result in decreased glucose-dependent expression of decorin, a
potent extracellular inhibitor of TGF-β. As expected, patients
with ATS exhibit elevated TGF-β signaling in their vessel walls
[99].
2.3. Primary pulmonary hypertension and familial pulmonary
hypertension
Primary pulmonary arterial hypertension (PAH) is character-
ized by intense remodeling of small pulmonary arteries by myo-
fibroblast and smooth muscle proliferation, resulting in sustained
elevation of pulmonary vascular resistance, arterial pressure, and
ultimately right ventricular heart failure leading to cardiac arrest
[100,101]. There are two types of PAH; a sporadic or idiopathic
PAH (IPAH), and hereditary or familial PAH (FPAH). Genetic
analysis has identified a heterozygous germ-line mutation in
BMPR2 associated with both IPAH and FPAH.BMPR2mutations
have been identified in 70% of families with FPAH and in up to
40% of patients diagnosed with IPAH [102,103]. 71% of the
mutations in BMPR2 are nonsense, frameshift, splice-site defects,
or gene re-arrangements resulting in a truncated mRNA transcript
that is prone to nonsense-mediated decay. Additional mutations
have been identified that affect the ligand binding, transmem-
brane, and cytoplasmic domains [103]. As disease onset varies
between family members and unrelated carriers have the same
mutation, there are likely additional genetic and/or environmental
modifiers that contribute to the pathogenesis of this disease and to
full disease penetrance [103]. There is a subset of HHT patients
that also present with clinical symptoms of PAH. These patients
have mutations in both ACVRL1 and BMPR2 [104], suggesting
that ALK1 signaling may also contribute to PAH.
The mechanisms by which BMPR2 mutations result in
pulmonary hypertension remain unclear. A disease causing role
for BMPRII is supported by transgenic mouse models. BMPRII
is critical for early embryonic development as homozygous
mutant mice die shortly after conception, due to the inability to
derive mesoderm [105]. To define the function of BMPRII
during development, a knock-out mouse was developed that
expresses a BMPRII mutant lacking half of the ligand-binding
domain. These mice die mid-gestation with severe liver defects
and outflow tract defects in the heart, including lack of septation
of the conotruncus below the valve level and an interrupted
aortic arch, a phenotype known in humans as persistent truncus
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reduced in mice using shRNA, the pulmonary vessel walls had
regions lacking smooth muscle cells, were highly disorganized,
and were more prone to rupture [107]. These mouse phenotypes
exemplify the importance of BMPRII in development of the
pulmonary vasculature and suggest why mutations in BMPR2
result in PAH.
Heterozygous BMPR2mice exhibit mild pulmonary hyperten-
sion and have an impaired vascular remodeling response to
prolonged low oxygen conditions [108], suggesting that haploin-
sufficiency of BMPRII contributes to this disease. These hetero-
zygous mice also develop elevated right ventricular systolic
pressure and vascular remodeling when exposed to inflammatory
agents [109]. In addition, expression of a dominant negative
BMPRII in smooth muscle cells in mice results in elevated pul-
monary arterial hypertension, and an increase in pulmonary
arterial muscularization [110]. The benefits of increasing BMPRII
levels on reducing the clinical manifestations of PAH have been
assessed using a rat model; delivery of an adenoviral vector
expressing BMPRII to the pulmonary vascular endothelium sig-
nificantly reduced the pulmonary hypertensive response to
chronic hypoxia [111].
In terms of signaling mediated by BMPRII, BMPRII is
unique in the context of TGF-β superfamily type II receptors in
that it possesses a long cytoplasmic domain after the kinase
domain. Mutations in this region have been identified in PAH,
and some of these mutations disrupt interaction of BMPRII with
receptor activated C-kinase 1 (RACK1). As RACK1 is required
for BMP-mediated Smad1 phosphorylation and inhibition of
proliferation in pulmonary arterial smooth muscle cells, this
defines one potential mechanism of action for BMPR2mutations
in this disease [112]. Recently, a link was established between the
inflammatory cytokine interleukin 6, which has been implicated
in PAH, and BMP signaling in a PAH mouse model. BMPR2
knock-out mice have high levels of IL-6 and overexpressing IL-6
induced the transcription of the BMP responsive gene Id1 [113].
Finally, the effects of serotonin, which induces PAH in rats, are
more pronounced inBMPR2 knock-out mice, suggesting that loss
of BMP signaling synergizes with several signaling pathways to
contribute to the pathogenesis of PAH [114]. This mechanistic
data suggests that PAH is a complex disease that clinically
manifests as a result of a variety of genetic and environmental
modifiers, explaining the clinical heterogeneity of PAH.
2.4. Pre-eclampsia
Pre-eclampsia, or pregnancy-associated hypertension, is a
major cause of maternal, fetal, and neonatal mortality world-
wide. A diagnosis of pre-eclampsia is made when patients
develop new hypertension and increased proteinuria during their
pregnancy. Early diagnosis and treatment is important as this
condition, if untreated, can progress to a severe form resulting in
maternal central nervous system, liver, and renal dysfunction,
bleeding related to thrombocytopenia, preterm delivery, fetal
growth restriction, abruptio placentae, and perinatal death, as
well as predisposing the mother to a greater long term risk of
developing coronary heart disease and stroke [115].Several recent studies identified high levels of soluble endoglin,
formed by ectodomain shedding of cell surface endoglin, in
patients exhibiting pre-eclampsia, with levels rising prior to
clinical pre-eclampsia, and correlating with disease severity
[116,117]. Soluble endoglin may function by binding to TGF-β1
and preventing it from binding to its receptors on endothelial cells,
resulting in decreased activation of eNOS and decreased
production of the potent vasodilator, nitric oxide. This results in
vasoconstriction, which induces hypertension in patients [116].
The precise mechanisms of how soluble endoglin contributes to
pre-eclampsia are still being defined. However, the use of endoglin
as a predictive or prognostic marker for pre-eclampsia is currently
being evaluated using serum from expectant mothers, with current
data supporting a strong relationship between disease severity and
endoglin levels [118].
2.5. Atherosclerosis
Atherosclerosis is a disorder involving endothelial dysfunction,
vascular inflammation, and accumulation of lipids, cholesterol,
and cellular debris within the intima of medium and large sized
arteries resulting in plaque formation and acute and chronic
luminal obstruction. Atherosclerosis is the primary cause of
cardiovascular disease and stroke. TGF-β ligands and their
receptors are expressed by endothelial cells, smooth muscle cells,
macrophages, and T-cells in human atherosclerotic lesions [119].
Although the role of the TGF-β signaling pathway in athero-
sclerosis is controversial, with some studies suggesting a pro-
atherosclerotic effect [119,120], most studies support a role for
TGF-β in inhibiting atherosclerosis and atherosclerotic progres-
sion. First, TGF-βmediates cellular effects thatwould be expected
to inhibit atherosclerosis including inhibiting the proliferation and
migration, and stimulating apoptosis of vascular smooth muscle
cells and endothelial cells, and potently inhibiting the immune
system. Second, in murine models of atherosclerosis; blocking
TGF-β activation through expression of apolipoprotein [121],
blocking systemic TGF-β signaling through expression of soluble
TβRII [122] or neutralizing TGF-β antibodies [123], blocking
TGF-β signaling in T-cells through expression of dominant
negative type II receptors [124], or decreasing circulating levels of
TGF-β1 by targeted deletion of one allele is sufficient to increase
atherosclerosis [125], while increasing TGF-β levels indirectly
with Tamoxifen is sufficient to decrease atherosclerosis [126].
Third, smooth muscle cells isolated from human atherosclerotic
lesions are resistant to the antiproliferative and apoptotic effects of
TGF-β, and containmutations and/or decreasedTβRII expression
[127,128]. Fourth, TGF-β appears to stabilize atherosclerotic
plaques by stimulating collagen secretion and promoting the
formation of a collagen-rich fibrous cap [120]. Finally, in an
atherosclerotic mouse model (LDLR−/−), delivery of an adeno-
associated virus type 2 vector expressing active TGF-β1 sup-
pressed the formation of atherosclerotic lesions [129].
TGF-β signaling has been linked to risk of myocardial
infarction (MI), which occurs when the heart is deprived of
oxygen. Several TGFB1 polymorphisms have been examined in
MI patients [130]. The−509C/T polymorphism is associatedwith
an increased incidence of myocardial infarction in men,
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sion, diabetes, and high cholesterol levels. Interestingly, this
polymorphism was only associated with increased risk of MI in
males and not in females [131], which was also the case for
another polymorphism, T29C, which was only associated with an
increased risk of MI in middle-aged Japanese men [132].
However, a recent study performed on a larger cohort did not
confirm an association of the −509C/T polymorphism with MI;
however, it was associatedwith an increased risk of stroke, as was
the case for the codon 10 Leu/Pro TGFB1 polymorphism [133].
While the role of TGF-β in atherosclerosis has been well
defined, the role of other superfamily members, including the
BMPs and activins is only beginning to be established. Similar to
TGF-β1, activin appears to suppress atherosclerosis, as over-
expression of activin decreases vascular smooth muscle cell
migration into the intima in an atheroscleroticmousemodel [134].
BMP-2, BMP-4, and BMP-6 levels are increased in advanced
atherosclerotic lesions and these elevations are associated with
increased levels of calcification, suggesting a role for BMPs in
promoting advanced atherosclerotic lesions [135,136].
2.6. Restenosis
Restenosis refers to the exuberant fibrotic reaction, intimal
proliferation, and remodeling in response to revascularization
therapies including angioplasty, stenting, and atherectomy. Rest-
enosis remains a major barrier to the effectiveness of these inter-
ventions.While TGF-β is thought to protect from atherosclerosis,
several lines of evidence support increased TGF-β signaling as a
major contributor to restenosis. First, expression of all TGF-β
isoforms, TβRI, and TβRII is increased after angioplasty- induced
vascular injury [137]. Second, overexpression of TGF-β1 is able
to stimulate neo-intimal hyperplasia and fibrosis [138], a major
contributor to restenosis. Indeed, TGF-β is one of the most
important ECM regulators in the cell; increasing extracellular
matrix (ECM) protein expression and inhibiting the degradation of
ECM components, resulting in a net accumulation of ECM [139].
The major ECM proteins produced by fibroblasts in the heart
are Type I and Type III collagen, and these are responsible for
most fibrotic processes occurring after vascular injury, including
angioplasty [140]. Third, decreasing TGF-β signaling by
decreasingTGF-β1 levels with ribozymes [141], or using pharma-
cological inhibitors of TGF-β signaling [142] is able to decrease
neo-intimal hyperplasia and remodeling. Finally, overexpression
of Smad7 in rat carotid arteries was able to abrogate restenosis
after angioplasty, suggesting that blocking TGF-β signaling is
capable of preventing restenosis [143].
2.7. Hypertension
Hypertension is a global medical problem that places indi-
viduals at risk for long term renal, cerebral, and coronary heart
disease. While environmental factors including obesity and salt
intake contribute to the onset of hypertension, approximately 50%
of hypertension is thought to have a genetic basis [101], with
several documented links between increased TGF-β signaling
and hypertension [140]. Emilin1, a secreted glycoprotein asso-ciated with the extracellular matrix of blood vessels, functions to
antagonize TGF-β1 signaling by binding to the precursor form of
TGF-β and decreasing its proteolytic processing into the active
form. In both EMILIN1 homozygous null mice and heterozygous
mice, the systolic blood pressure is significantly increased in all
animals, regardless of age, with decreased Emilin1 expression
resulting in increased TGF-β1 signaling, reduced vessel size, and
increased vascular resistance. A direct role for TGF-β1 in the
EMILIN1 null phenotype is supported, as genetic suppression
of TGF-β1 in EMILIN1 knock-out mice results in a return to a
normotensive state [144]. In addition, in a rat hypertensionmodel,
TGF-β neutralizing antibodies are sufficient to decrease blood
pressure and subsequent renal failure [145]. Importantly, in hu-
mans, polymorphisms in TGFB1 resulting in increased TGF-β1
expression have been linked to the development of hypertension,
with a direct correlation between TGF-β1 levels andmean arterial
pressure [146].
TGF-β signaling is also upregulated by the renin–angiotensin–
aldosterone axis [147], a critical regulator of blood pressure.
Angiotensin II (Ang II) directly stimulates TGF-β1 expression
at the mRNA level, and enhances its conversion to the active
form at the protein level by increasing Thrombospondin-1 levels
[148,149], see Fig. 2. In addition, Ang II increases TβRII mRNA
expression [150], angiotensin III stimulates TGF-β1 expression
at the mRNA level [151], and aldosterone induces TGF-β1 ex-
pression [152], see Fig. 2. An important role for the renin–
angiotensin–aldosterone axis in increasing TGF-β signaling is
supported by the ability of angiotensin converting enzyme (ACE)
inhibitors and angiotensin I receptor antagonists, both used in the
treatment of hypertension, to reduce renal TGF-β1 production.
Renin–angiotensin system inhibitors includingACE inhibitors are
effective in reducing renal disease progression associated with
diabetic nephropathy in rat models. When a TGF-β neutralizing
antibody was administered in combination with an ACE inhibitor,
there was a synergistic effect on inhibiting renal injury and pro-
teinuria [153]. The exact mechanisms of how TGF-β superfamily
members contribute to renal injury warrants further investigation.
2.8. Hypertrophic cardiomyopathy/congestive heart failure
Cardiomyopathy refers to diseased heart muscle and is classi-
fied into three different types, dilated, hypertrophic and restrictive,
based on anatomical and physiological parameters. Eventually, if
untreated, cardiomyopathy will progress, resulting in congestive
heart failure due to contractile dysfunction, arrhythmias, ulti-
mately leading to death [147]. In the pathogenesis of cardiomyo-
pathy, elevated levels of angiotensin II increase TGF-β levels and
TGF-β signaling, as discussed above. These elevated levels of
TGF-β are important for the pathogenesis of cardiac hypertrophy
as angiotensin II is unable to induce hypertrophy in mice
lackingTGFB1 [147,154]. Importantly, elevated circulating levels
of TGF-β1 are found in patients with dilated, hypertrophic,
and restrictive cardiomyopathy, and as with hypertension, ACE
inhibitors and angiotensin I receptor antagonists, which are used
therapeutically for cardiomyopathy patients, may function by
reducing TGF-β1 production and subsequent collagen production
in the heart. In addition, in humans, polymorphisms in TGFB1
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dilated cardiomyopathy [155].
Other TGF-β superfamily members have also been implicated
in the pathogenesis of cardiomyopathy. Specifically, BMP-10
expression is increased in the ventricles of hypertensive rats with
cardiac hypertrophy, and in humans, a polymorphism in BMP10,
which leads to increased BMP-10 secretion/bioactivity, was
identified in patients with dilated cardiomyopathy [156]. In mice,
expression of BMP-10 increases in the ventricular trabecular
myocardium when cardiac development shifts from patterning to
growth and chamber maturation, and BMP-10 is required for both
of these processes [157]. When BMP-10 is absent, there are
elevated levels of p57Kip2, which is associated with reduced
proliferation of cardiomyocytes, and reductions in the cardiogenic
transcription factors NKX2.5 and MEF2C in the developing
myocardium. This results in severe cardiac malformations
including hypoplastic ventricular walls and absence of ventricular
trabeculae, both of which contribute to the early embryonic lethal
phenotype [157]. In addition, myostatin (GDF-8) has been impli-
cated in contributing to cardiac hypertrophy, as myostatin expres-
sion is elevated in hypertrophic cardiac tissue and myostatin
increases the growth of cultured cardiomyocytes [158].
3. Connective tissue diseases
3.1. Marfan syndrome and Marfan-like disorders
Marfan syndrome (MS) is a hereditary autosomal dominant
multisystem connective tissue disorder, which is characterized
clinically by cardiac abnormalities including aortic aneurysms,Fig. 2. The renin–angiotensin–aldosterone axis increases TGF-β1 expression and activ
then converted to Angiotensin II by Angiotensin Converting Enzyme (ACE). Angioten
signaling cascade to increase TGF-β1 mRNA levels [150]. Angiotensin II also directly
expression, which cleaves the LAP domain of TGF-β1 and converts TGF-β1 into its act
also increases TGF-β1 mRNA levels. Aminopeptidase A converts Angiotensin II into
aldosterone axis effects on TGF-β1 expression and activity can be attenuated by ACEaortic dissections, and mitral valve abnormalities; skeletal
manifestations, and vision problems [159,160]. MS has been
linked to a mutation in the extracellular matrix protein fibrillin-1
[98]. Fibrillin polymerizes to form microfibrils, which normally
stabilize latent TGF-β-binding proteins and maintain TGF-β
in its inactive state, while the mutant fibrillin proteins in
MS patients fail to do so, resulting in elevated levels of active
TGF-β. Fibrillin mutations have been identified in the majority
of patients with MS. However, up to 34% of patients have no
identified mutation in FBN1, suggesting that others genes con-
tribute to this disease. Recently, mutations were identified in
TGFBR1 and TGFBR2 in patients with MS [160–162]. Those
patients with TGFBR1 and TGFBR2 mutations are referred to
as having MS type II, while those with FBN1 mutations are
referred to as having MS type I. These TGFBR1 and TGFBR2
mutations affect the kinase domain of the receptors and are
predicted to result in loss of function [96,98,161]. While similar
mutations in Loeys–Dietz syndrome paradoxically result in
increased TGF-β signaling [96], whether this is the case in MS
remains to be established. TGFBR2 mutations resulting in MS
are associated with more extensive and progressive aortic and
peripheral vascular disease, earlier disease onset, andmore diffuse
arterial disease than those patients with the FBN1 mutation,
suggesting that patients with TGF-β receptor mutations may have
a distinct disease pathogenesis than those with FBN1 mutations
[159]. Clearly, context-dependent alterations in TGF-β signaling
are involved in the pathogenesis of MS.
Mutations in TGF-β receptors have also been identified in
Marfan-like disorders. Specifically, a mutation affecting the
kinase domain of TβRI has been identified in patients withity. Renin mediates the conversion of Angiotensinogen to Angiotensin I, which is
sin II binds to its receptor (AT1R) to activate a NADPH oxidase/p38 MAPK/AP-1
increases p38 and JNK MAPKs signaling to increase thrombospondin-1 (TSP-1)
ive form [149]. Furthermore, Angiotensin II promotes aldosterone secretion, which
Angiotensin III, which also increases TGF-βl expression. The renin–angiotensin–
inhibitors or angiotensin receptor blockers, such as losartan [147].
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of skull sutures and aortic dissection [163]. In addition, a
TGFBR2 mutation resulting in defective splicing of TGFBR2
was identified in patients with Sphrintzen–Goldberg syndrome,
which is associated with premature closure of skull sutures and
mental retardation [162,164]. Since these phenotypes overlap
for these Marfan-like disorders, more clinical analysis of
patients is required to understand the role of TGF-β superfamily
signaling in progression of these diseases.
In mouse models in which FBN1 mutants identified in MS
patients are expressed, there is increased TGF-β signaling in
multiple organs including in the lungs, heart, and aorta, con-
firming that fibrillin normally functions to downregulate TGF-β
signaling [161]. Importantly, administrating a TGF-β neutralizing
antibody to these mice diminishes the lung and mitral valve
manifestations ofMS [161,165], demonstrating the importance of
increased TGF-β signaling in the pathogenesis of this disease.
3.2. Fibrotic diseases
Fibrosis is a complex tissue disease that results from excessive
and abnormal deposition of extracellular matrix (ECM), which is
composed of fibronectin, laminin, vitronectin, and collagen, by
long term activation of myofibroblasts [166]. Myofibroblasts are
a specialized type of fibroblast that are normally activated during
wound healing [167]. If the build-up of ECM occurs in organs
such as the lungs, liver, kidneys, and skin, it can interfere with
organ function, and unabated, results in organ failure. Examples
of fibrotic diseases include skin fibrosis, vascular fibrosis, sys-
temic sclerosis, renal fibrosis, and liver fibrosis. As mentioned
briefly during the discussion of restenosis, TGF-β is a critical
regulator of extracellular matrix assembly and remodeling [166],
which stems from its first defined function as a potent stimulator of
wound healing [168]. As fibrosis has been described as a “wound-
healing response that has gone out of control” [169], excessive
TGF-β signaling has long been implicated in the pathogenesis of
fibrotic diseases, and has been the subject of several excellent
recent reviews [166,169]. TGF-β signaling through Smad3
directly promotes expression of type I collagen, a major compo-
nent of the ECM, during fibrosis [170]. Smad3 has a central role in
TGF-β induced fibrosis in several organ systems as: (1) skin
from SMAD3−/− mice is resistant to injury from ionizing radiation
with reduced recruitment of myofibroblasts [171]; (2) hepatic
stellate cells mediate fibrosis in the liver, and they require Smad3
to induce collagen expression [172]; (3) Smad3, and not Smad2,
is required for angiotensin II induced vascular fibrosis [173];
(4) increased levels of phosphorylated Smad3 are observed in
keloid (scar) fibroblasts [174]; and (5) SMAD3−/−mice are resistant
to bleomycin and TGF-β-mediated pulmonary fibrosis [175,176].
Another important effector of TGF-β induced fibrosis is con-
nective tissue growth factor (CTGF). TGF-β promotes CTGF
expression in fibroblasts, which promotes collagen synthesis and
myofibroblast differentiation [177,178]. CTGF binds directly to
TGF-β, and enhances its activity resulting in increased binding to
TβRI and TβRII [179]. CTGF can stimulate fibrosis directly by
promoting mesangial cell survival, via stabilization of the anti-
apoptotic protein Bcl-2, which is thought to promote renal fibrosisunder chronic pathological conditions such as diabetic nephropathy
[180]. It is thought that CTGF synergizes with other pathways,
including TGF-β, to induce fibrosis, as overexpressing CTGF
alone induced only mild pulmonary fibrosis in mice [181], but
potentiated the effects of bleomycin-induced fibrosis [178,182].
An additional contributor to fibrosis is epithelial to mesench-
ymal transition, a phenotypic conversion of epithelial cells into
mesenchymal cells, which is associatedwith increased expression
of fibroblast-associated proteins, such as alpha smooth muscle
actin (SMA). The contribution of EMT to fibrosis has been
extensively studied in the kidney, as it converts renal tubular
epithelial cells into fibroblasts, which produce large amounts of
ECM that accumulates in the kidneys, and interferes with their
function [183]. Progressive renal fibrosis is often associated with
diabetes [184]. The ERK and JNKMAPK pathways, and Smad2
mediate TGF-β-induced EMT in renal tubular epithelial cells
[185]. Integrin linked kinase (ILK) has also been implicated in
TGF-β-induced renal fibrosis, as expression of a dominant nega-
tive ILK inhibited TGF-β-inducedEMTof renal tubular epithelial
cells and inhibiting ILK in vivo inhibited EMT and fibrosis in a
renal fibrosis mouse model [186]. The importance of increased
TGF-β signaling in fibrosis has been validated therapeutically. A
TβRI kinase inhibitor significantly reduced renal fibrosis in the
db/db diabetic nephropathy model, which was associated with
reduced expression of collagen and fibronectin in the kidneys
[184]. Alternatively, delivering a TβRI inhibitor to proximal
tubular cells by conjugating it to the renal carrier protein lysozyme
suppressed the activation of tubular cells and fibroblasts, reduced
inflammation, and decreased levels of the fibrotic markers
vimentin and αSMA in the unilateral ureteral obstruction rat
model of renal fibrosis [187].
In addition, TGF-β regulates the expression of other proteins
involved in executing the fibrotic cascade including: (1) regulation
of the expression and activity of extracellular remodeling pro-
teases including matrix-metalloproteinases, and their inhibitors,
the tissue inhibitors of metalloproteinases [188]; (2) increasing the
expression of the vasoconstrictive peptide endothelin-1, which has
been shown to contribute to persistent fibrosis by inducing
fibroblasts to produce and secrete ECM [189]; and (3) regulating
the activity of the Rho family of small GTPases, which have been
implicated in mediating TGF-β-induced fibrosis [139]. Overall
TGF-β is a critical regulator of extracellular matrix production;
and therefore, increased TGF-β signaling is a critical contributor
to the progression of fibrotic diseases.
4. Skeletal and muscular disorders
Bone is a mineralized tissue that provides mechanical support,
protects organ systems, regulates calcium levels in the blood, and
provides an environment for hematopoiesis. Bone forms through
the deposition and mineralization activity of osteoblasts, and is
constantly remodeled through the coordinated action of osteo-
blasts and osteoclasts, which serve to resorb bone [190]. TGF-β
superfamily members are abundantly expressed in the bone
environment and regulate a number of important bone processes.
TGF-β1 signaling has been extensively studied in bone since it is
the predominant TGF-β isoform expressed in bone. TGF-β1 has
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cruitment of osteoblast progenitors, stimulation of their prolifera-
tion and differentiation, and inhibition of osteoblast apoptosis
[191]. The TGF-β1 knock-out mice have a skeletal phenotype
including reduced bone growth and mineralization, as well as
reduced elasticity [192], and reduced alkaline phosphatase activity
[193].
BMPs critically regulate bone homeostasis; they were initially
given their name by Urist based on their ability to induce ectopic
bone formation [194]. When BMP2 and BMP4 are both knocked
out in the limb bud mesenchyme of mice, there is severe im-
pairment of bone formation [195]. Although knocking out BMP2
alone results in no obvious bone defects in mice; these mice are
more susceptible to bone fractures [196]. When the BMP type I
receptors BMPR1A and BMPR1B are knocked out in chondro-
cytes, there are defects in chondrocyte proliferation and dif-
ferentiation, resulting in chondrodysplasia and disrupted bone
formation [197].
4.1. Camurati–Engelmann disease
Camurati–Engelmann disease (CED) is an autosomal dominant
disorder that affects the diaphysis of long bones and results in
increased bone density, bonemarrow dysfunction, muscular weak-
ness, and severe bone pain [190]. This disease has been linked to
mutations in TGFB1, with 9 distinct mutations identified thus far
[198]. The majority of CED linked TGFB1 mutations are in the
latency associated domain of TGF-β1 [190], while one mutation
has been identified that affects the signal peptide of TGF-β1 [198].
The location of these mutations suggests that increased TGF-β
signaling is responsible for the pathogenesis of CED. Indeed, when
known CED TGFB1 mutants are expressed in human epithelial
kidney cells, these mutants result in increased autocrine TGF-β1
production and TGF-β-mediated transcription [198].
4.2. Fibrodysplasia Ossificans Progressiva
Fibrodysplasia Ossificans Progressiva (FOP) is an autosomal
dominant disease characterized by the progressive ossification of
skeletal tissue either spontaneously or in response to trauma. A
heterozygous mutation in ACVR1 (encodes ALK2) has been
tightly linked to the disease, with a single mutation conserved in all
familial and sporadic cases of FOH [199]. The disease causing
mutation inACVR1 results in an arginine to histidine substitution in
the GS domain [190,199]. While this mutation does not affect the
expression of ALK2, structural protein modeling predicts that this
mutation would create a pH-sensitive switch within the activation
domain of the receptor resulting in ligand-independent activation
of ALK2 [200]. Indeed, increased ALK2 receptor activity as a
contributor to the pathogenesis of FOP is supported by data from
signaling studies, as lymphocytes from FOP patients exhibit
elevatedBMP-mediated p38 activation and increased basal expres-
sion of BMP responsive genes [201]. Lymphocytes from FOP
patients also have increased expression of BMP-4 and increased
expression and activity of ALK3 [201]. As ALK2, BMP-4, and
ALK3 are all altered in FOP, this suggests that aberrant signaling
through the BMP signaling pathway contributes to the pathogen-esis of FOP. In support of this, mice overexpressing BMP-4 under
control of the neuron-specific enolase promoter develop severe
postnatal heterotopic ossification, which closely resembles human
FOP. Crossing these mice with mice overexpressing noggin in-
hibits disease progression supporting increasedBMP signaling as a
contributor to the pathogenesis of FOP [202].
4.3. Hunter–Thompson and Grebe-type chondrodysplasias
Hunter–Thompson (CHTT) andGrebe-type chondrodysplasias
(CGT) patients both have pronounced shortening of limb bones
and are predisposed to severe knee dislocations; however, CGT
patients have a more severe phenotype than CHTT patients. Both
CHTT and CGT are caused by mutations in GDF5, with CGT
patients having amutation in a conserved cysteine in the functional
domain of GDF-5 [203], while CHTT patients have missense
mutations in GDF5 that result in loss of GDF-5 expression [204].
GDF5 deficient mice have similar phenotypes to humans with
these syndromes, including structurally weaker Achilles tendons
with reduced collagen composition [205]. Analysis of GDF-5
function in chick skeletal development demonstrates that GDF-5 is
required for cartilage condensation and chondrocyte proliferation
[203].
4.4. Osteoporosis
Osteoporosis is a common disease that occurs when there is an
imbalance between bone resorption and formation. Patients
present with decreased bone mass and increased susceptibility to
fractures. Women are at a two-fold greater risk than men for
developing this disease. The genetic contributors to osteoporosis
are still being defined as there are likely many genetic modifiers
that contribute to this disease [206]. Several TGF-β superfamily
members have been implicated as candidate genes in osteoporo-
sis, including TGFB1, BMP2, BMP4, and SOST (sclerostin)
[206]. Several polymorphisms in TGFB1 have been identified in
patients with osteoporosis; G(−1639)-A, C(−1348)-T, C(−765)
insC, T(29)-C, G(74)-C, 713-8delC, C(788)-T, and T(816–20)-C
[207]. Many of these TGFB1 polymorphisms are associated with
higher serum TGF-β1 levels and significantly lower bone mass
[208], and patients with one of these polymorphisms exhibit a
reduced response to vitamin D treatment [209]. Another study
identified single-nucleotide polymorphisms in several TGF-β path-
way components in patients with osteoporosis including TGFBR1,
TGFBR2, SMAD2, SMAD3, SMAD4, and SMAD7 [210]. The
relevance of these polymorphisms remains to be established.
Bone morphogenetic proteins have also been implicated in
contributing to osteoporosis since they are critical regulators of
bone homeostasis. Polymorphisms inBMP2 have been associated
with low bone mineral density and increased fracture incidence
[211], although a subsequent study on a larger population did
not confirm this result [212]. In addition, a polymorphism in
BMP4 has been identified that affects hip bone density in post-
menopausal women [213]. Finally, Resveratrol, a natural com-
pound with estrogenic activity, has been explored as a potential
osteoporosis therapy due to its ability to potently stimulate osteo-
clast differentiation and increase bone mass in a rat model.
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expression and stimulating BMP-2 mediated osteoblast differ-
entiation [214].
4.5. Sclerosteosis and Van Buchem disease
Sclerosteosis and Van Buchem disease (VBD) are closely
related rare autosomal recessive diseases that affect the skeletal
system [215]. Both diseases are associated with overgrowth of the
skull and jaw, facial palsy, hearing loss, and loss of smell.
Sclerosteosis is more severe than VBD as patients have increased
intracranial pressure and have been reported to die suddenly from
brain stem impaction. Sclerosteosis has more clinical features
including syndactyly, gigantism, dental malocclusion, and nail
hypoplasia. These diseases have been linked to the same gene
with Sclerosteosis resulting from mutations within SOST
(encodes sclerostin) and VBD resulting from a 52kB deletion
32kB downstream of SOST, which deletes an enhancer element
that regulates SOST expression [215]. Four mutations in SOST
have been identified in patients with Sclerosteosis, including two
mutations that result in a premature stop codon in exon 2, one
mutation that results in a premature stop codon in exon 1, and a
base substitution, that results in an incorrectly spliced message
[215–217].
Sclerostin is a BMP antagonist abundantly expressed in long
bones and cartilage [34,215,218]. This restricted expression is
consistent with patients exhibiting only skeletal clinical manifes-
tations. Sclerostin is expressed exclusively by osteocytes in
human bone, and it inhibits the differentiation and mineralization
activity of osteoblasts in vitro. Therefore, sclerostin is thought to
negatively regulate bone mass. The current model for the patho-
genesis of these diseases is that sclerostin is normally produced by
osteocytes and transported to the bone surface, where it inhibits
the later stages of bone formation by binding and sequestering
BMPs. In Sclerosteosis andVBDpatients, as there is no inhibitory
signal, osteoblasts continue to deposit bone leading to increased
bone mass [218]. Patient's clinical manifestations support this
model with bone biopsies indicating increased activity of osteo-
blasts and higher serum alkaline phosphatase levels, which
contribute to patients being resistant to acquiring bone fractures
[215]. The importance of sclerostin in inhibiting bone mass is
evident from the sclerostin overexpressing mouse, which has
reduced osteoblast activity and bonemass, aswell as disorganized
bone architecture [219]. Taken together these studies demonstrate
that careful regulation of sclerostin is critical for normal bone
development and growth.
4.6. Brachydactyly and Symphalangism
Brachydactyly type C (BDC) is associated with shortening
and occasionally the complete loss of digits. Brachydactyly type
A2 (BDA2) is an autosomal dominant disorder resulting in
shortening and lateral deviation of the index fingers and, to a
variable degree, shortening and deviation of the first and second
toes. These diseases are both associated with defects in signaling
through GDF-5 and ALK6, with mutations inGDF5 that reduce
the binding affinity of GDF-5 to ALK6 in BDC, and hetero-zygous missense mutations in the GS and kinase domains of
ALK6 in BDA2 [220]. The importance of GDF-5 and ALK6 in
skeletal development is evident from the phenotype of the
knock-out mice, with GDF5 knock-out mice having severe
limb reduction and joint malformations [221], and BMPR1B
knock-out mice failing to generate digit cartilage, similarly to the
human phenotype [220].
Symphalangism (SYM1) is a disease that is characterized by
fusion of the joints in the hands and feet. SYM1 is also associated
with defects in signaling through GDF-5 and ALK6, with
mutations in GDF5 increasing the binding affinity of GDF-5 for
ALK6. SYM1 has also been linked to mutations in the BMP
antagonist NOG (encodes noggin), which are predicted to de-
crease noggin's ability to bind to BMPs and GDFs [222]. NOG
knock-out mice exhibit cartilage overproduction and joint mal-
formations, while NOG heterozygotes have a similar phenotype
to human SYM1 with loss of joint cartilage and fusion [221],
supporting a role for dysregulated noggin function in this disease.
4.7. Duchenne muscular dystrophy
Duchenne muscular dystrophy (DMD) is the most common
inherited lethal muscle wasting disease. Patients present at a
young age, with muscle weakness that interferes with their
mobility. Eventually patients die from cardiovascular or respira-
tory failure. This disease is caused by mutations in muscle
dystrophin, resulting in insufficient protein levels. There is some
phenotypic variability in patients, suggesting that there are other
genetic or environmental modifiers that contribute to this disease
[223]. Recently, several missense mutations in GDF8 (encodes
myostatin) were identified in DMD patients [223]. Myostatin is a
muscle-specific TGF-β superfamily ligand that functions to limit
muscle growth; as evident from myostatin deficient mice and
cattle, which show a marked increase in body weight, muscle
mass, and strength [224,225]. In addition, crossing a DMDmouse
model with a GDF8 knock-out mouse produced mice with in-
creased muscle mass and stronger muscle [226], while adminis-
tration of myostatin blocking antibodies to a DMD mouse model
increased body weight, muscle mass, size, and strength with no
long term obvious side effects [225,226]. Finally, a homozygous
mutation inGDF8was identified in an infant that exhibited gross
muscle hypertrophy [227]. Taken together, these observations
suggest mutations in myostatin may contribute to the pathogen-
esis of DMD, and that targeting myostatin function may be a
useful therapeutic strategy for treating the muscle wasting symp-
toms in DMD patients.
5. Reproductive disorders
TGF-β superfamily members exert critical functions in the
female reproductive system. They regulate all aspects of ovarian
follicle development; primordial follicle recruitment, granulosa
and theca cell proliferation, gonadotropin receptor expression,
oocyte maturation, ovulation, luteinization, and corpus luteum
formation [228]. The most well studied TGF-β superfamily
members in the reproductive system are activin and inhibin,
which were originally identified as components of gonadal fluid
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release, respectively [229]. Inhibin was subsequently found to
antagonize activin signaling by binding to TβRIII and sequester-
ing activin type II receptors into a complex so they cannot trans-
duce activin mediated signals [15]. Follistatin is another activin
antagonist that binds to activin and prevents activin from binding
to cell surface receptors. Follistatin and inhibin also antagonize
specific BMP-mediated signals [229]. The importance of activin
and inhibin in normal reproductive processes is evident from the
phenotypes in murine models: (1) inhibin A overexpressing male
mice have decreased testis size and female mice do not have
mature follicles due to inadequate FSH secretion from the pitui-
tary gland [230]; (2) ACVR2 knock-out females are infertile and
males have small testis, phenotypes that are similar to the inhibin
overexpressing mice [231]; (3) activin-beta subunit knock-out
mice have delayed child-birth and nursing defects [232]; and (4)
knocking out FST (encodes follistatin) in granulosa cells of the
postnatal ovary results in reduced reproductive capacity and often
infertility [233]. We will now discuss the contribution of these
TGF-β superfamily members to specific reproductive diseases.
5.1. Premature ovarian failure
Premature ovarian failure (POF) occurs in up to 1% of
women and is a common cause of infertility. POF is diagnosed
when there is absent menstruation or premature depletion of
ovarian follicles before the age of 40 years. POF is associated
with high levels of gonadotropins and estrogen [234]. A con-
tributor to POF is ovarian dysgenesis (OD), which is defective
gonadal development where the ovaries can be replaced by a
gonadal streak rather than true ovaries. Most cases of OD are
associated with major X-chromosome abnormalities; however,
OD can affect patients with normal X chromosomes. BMP-15
has been implicated in contributing to OD, with several muta-
tions identified in BMP15 in patients with OD, but not in
control subjects, including a heterozygous substitution mutation
in the pro region of BMP15 (Y235C) [235,236]. Animal models
have supported a role for BMP-15 in ovarian development, as
GDF9/BMP15 double knock-out mice have fewer fertilized
oocytes and those that do become fertilized take longer to
develop to the blastocyst stage [237]. Mutations in BMP15 in
sheep are also associated with an increased ovulation rate and
infertility in a dosage-sensitive manner [238].
A mutation in INHA (encodes inhibin alpha subunit) has
been identified in many patients with POF (A257T) [239,240].
The effects of this mutation on inhibin-mediated suppression of
activin activity were assessed by transfecting an activin respon-
sive luciferase promoter into multiple activin responsive cell
lines. Adding wild-type inhibin alpha suppressed the activity of
this promoter 5 fold, whereas the POF-associated INHA mutant
form exhibited no inhibitory activity. This inability to suppress
activin signaling was not a result of inappropriate dimerization
with the inhibin beta subunit [239]. An inhibin binding receptor,
TGFBR3, has also been implicated in POF as there is an
increased occurrence of a polymorphism in exon 12 of TGFBR3
in patients with POF. The consequences of this mutation in
patients with POF requires further investigation [241].5.2. Persistent Müllerian duct syndrome
The Sertoli cells of the testes produce two hormones seven
weeks post gestation that are required for the male embryo to
develop a normal internal reproductive tract; (1) testosterone
induces theWolffian ducts to differentiate into epididymidis, vas
deferens, and seminal vesicles; and (2) Müllerian-inhibiting
substance (MIS), which causes regression of the Müllerian
ducts. If MIS is absent, then these ducts develop into the
Fallopian tubes, uterus, and upper vagina as observed in female
embryos [242,243]. In a rare autosomal recessive disorder, there
is persistence of Müllerian duct derivatives including the uterus
and fallopian tubes in genetic males otherwise normally
virilized. Persistent Müllerian duct syndrome (PMDS) results
from a mutation in MIS, that leads to very low levels of circu-
lating MIS even before puberty, when MIS levels would nor-
mally be high [244]. Patients with PMDS can be homozygous or
heterozygous. Although most patients are homozygous, the
clinical manifestations in heterozygous patients indicate that
PMDS can arise fromMIS haploinsufficiency [244]. There have
been 38 mutations in MIS identified to date, mostly missense
that affect the bioactive carboxy terminus. MIS mutants, when
expressed in epithelial cells, are retained in the endoplasmic
reticulum and not secreted. Structural modeling predicts that
many of these mutations would affect the folding and stability of
MIS [243].
In PMDS patients with normal levels of serumMIS, mutations
in AMHR2 [encodes MIS Type II receptor (MISRII)] have been
identified [244]. Patients with MIS or AMHR2 mutations are
clinically indistinguishable. Mutations in AMHR2 affect the
entire gene and result in inappropriate targeting of the receptor
to the cell surface [245], truncation before the transmembrane
domain leading to a soluble unstable receptor [243,245], trunca-
tion immediately after the transmembrane domain that results in a
dominant negative receptor, or disruption of the substrate-binding
site of the kinase domain [245,246]. There is a subset of PMDS
patients that do not carry mutations in MIS or AMHR2. These
patients have been screened for mutations in other TGF-β super-
family members including ACVR1, BMPR1A, and BMPR1B;
however, no mutations in these genes have been identified to date
[243].
6. Hereditary cancer syndromes
6.1. Juvenile Polyposis syndrome
Juvenile Polyposis syndrome (JPS) is an autosomal dominant
disorder that causes multiple hamartomatous polyps in the
gastrointestinal tract, predominantly in the colon, at a young age,
and predisposes individuals to gastrointestinal tract cancers,
including colorectal, gastric, small intestinal, and pancreatic
cancer, with a lifetime risk for colorectal cancer as high as 50%.
Germ-line mutations in three TGF-β superfamily members have
been identified in JPS patients, with 20% having SMAD4 muta-
tions, 20% having BMPR1A mutations, and ENG mutations
have been established in a very small subset of patients [73,247,
248]. Similarly to other human cancers, the majority of the
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tions have also been identified in the linker region and one in the
MH1 domain. The majority of mutations in BMPR1A are within
the kinase domain. As about a third of JPS patients do not have
mutations in SMAD4 or BMPR1A, other TGF-β superfamily
members might be mutated in this disease. Thus far, BMPR1B,
BMPR2, and ACVRL1 have been excluded as potential genes
that contribute to JPS [73].
6.2. Hereditary nonpolyposis colorectal cancer
The most common hereditary condition that predisposes
patients to developing colorectal cancer is the autosomal dominant
disorder Hereditary nonpolyposis colorectal cancer (HNPCC).
HNPCC results from germ-linemutation of geneswithin theDNA
mismatch repair system, which contribute to microsatellite
instability. Microsatellites are repetitive DNA sequences that are
spread across the genome and are prone to mutation during DNA
replication, particularly when there are defects in the DNA
mismatch repair system [249]. The TGFBR2 gene is a hot spot for
inactivation in patients with HNPCC as it contains a 10 base pair
polyadenine repeat microsatellite sequence [250]. Indeed, up to
80% of colon cancer patients with HNPCC have a TGFBR2
mutation. Recently, a polymorphism in TGFBRI (TGFBR1⁎6A)
was identified in a subset of patients with HNPCC [251]. The
significance of this finding remains to be established.
6.3. Bannayan–Riley–Ruvalcaba and Cowden syndromes
Cowden-syndrome (CS) is an autosomal dominant cancer
syndrome associated with abnormal growths in various organs
that predisposes patients to breast, thyroid, and endometrial can-
cers. Bannayan–Riley–Ruvalcaba (BRR) is a disorder that mani-
fests at birth and is associated with gastrointestinal polyposis.
These diseases are usually associated with a PTEN mutation;
however, one patient with CS and BRR symptoms with no PTEN
mutation was identified as having a mutation in BMPR1A [252].
The contribution of this mutation to these syndromes remains to
be defined.
7. Sporadic cancer
The contribution of TGF-β signaling to human cancer has
been extensively studied and we and others have previously
reviewed this topic [253–255]. The TGF-β signaling pathway has
complex and contradictory roles in the pathogenesis of human
cancers. In general, TGF-β acts as a tumor suppressor early in
carcinogenesis, inhibiting growth and promoting differentiation
and apoptosis when appropriate, but then switches to a tumor
promoter later in carcinogenesis, promoting the growth, survival,
motility, invasion, and metastasis of tumors that have formed.
TGF-β affects both the cancer cells, regulating their growth and
survival, and the tumor microenvironment, regulating the
composition of the extracellular matrix, angiogenesis, and
immune surveillance. Indeed, TGF-β contributes to all aspects
of tumorigenesis including: (1) growth stimulation; (2) evasion of
apoptosis; (3) promotion of angiogenesis; (4) immune evasion;and (5) promotion of invasion and metastasis [253,256]. The
importance of the TGF-β signaling pathway in human cancers is
evident from the frequent alteration of TGF-β signaling
components in hereditary human cancers (Table 2) and sporadic
cancers (Table 3).
There is increasing evidence that the BMP signaling pathway,
in addition to being mutated in several hereditary cancer pre-
disposition syndromes, also contributes to sporadic cancer
progression. Similarly to TGF-β, BMPs contribute to numerous
aspects of tumorigenesis including: (1) increasing the motility
and invasiveness of prostate [257] and colon [258] cancer cells,
(2) stimulating the growth of pancreatic [259], and prostate and
bladder cancer cells [260], and (3) inhibiting the apoptosis of
colon cancer cells [258].
7.1. Breast cancer
TGF-β critically regulates normal mammary growth and
development and numerous alterations in the TGF-β signaling
pathway have been described in human breast cancer. At the
ligand level, a polymorphism in the TGFB1 gene, specifically a
thymine to cytosine transition in the 29th nucleotide in the
coding sequence that results in a leucine to proline substitution at
the 10th amino acid has been identified and linked to increased
serum levels of TGF-β1 and an increased risk of breast cancer
[261,262]. However, some studies have failed to confirm an
increased risk for carriers of this polymorphism in their cohort
[263]. In addition, this polymorphism has been examined as a
prognostic marker, with the C allele of the T29C polymorphism
predicting decreased survival for breast cancer patients [264]. A
polymorphism in the promoter of TGFB2 has also been iden-
tified that enhances gene transcription and increases TGF-β2
protein levels. This polymorphism has been associated with a 5
fold increase in lymph node metastasis [265].
In terms of the TGF-β signaling receptors, two polymorphisms
in TGFBR1 (TGFBR1⁎6A, Int7G24A) have been identified in
patients with breast cancer [266,267]. These polymorphisms may
serve as low penetrance tumor susceptibility alleles and have also
been described in colon, cervix, and ovarian cancer patients.
Recently the effect of these allelic variations on breast cancer risk
was assessed, with one study supporting an association of the
TGFBR1⁎6A allele with an increased risk of familial breast
cancer and as a potential marker for poorly differentiated breast
cancer [268], and another supporting an association of the
Int7G24A allele with invasion and metastasis [269]. Mutations or
alterations in TGFBR1 and TGFBR2 are infrequent in human
breast cancers. While a specific mutation of TGFBR1, a C to A
transversion at nucleotide 1160 of the gene, has been reported to
occur at high frequency (42%) in breast cancermetastases [270], a
subsequent study failed to confirm this observation [271]. We
recently demonstrated that there is frequent loss of TβRIII
expression in human breast cancers, due to loss of heterozygosity
of the TGFBR3 gene locus, transcriptional downregulation by
elevated TGF-β levels, and perhaps epigenetic regulation. Loss of
TβRIII expression contributes to the pathogenesis of breast
cancer, with a specific role in regulating breast cancer progression
and metastasis [272]. Loss of TβRIII expression correlated with
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from primary to metastatic disease. Importantly, restoring TβRIII
expression in breast cancer cells inhibited tumor invasiveness in
vitro and tumor invasion, angiogenesis, and metastasis in vivo.
Finally, low TβRIII levels predicted decreased recurrence-free
survival in breast cancer patients [272].
Mutations in SMAD2, SMAD3, and SMAD4 are infrequent
in human breast cancers [273]. Tissue array studies have sup-
ported this observation with 92% of human breast cancers
expressing Smad2 and Smad4, and are TGF-β responsive as
demonstrated by phospho-Smad2 staining, while only 2%
lacked Smad4 expression [274].
Other TGF-β superfamily ligands are also likely to have a role
in breast carcinogenesis. Breast cancers metastasize to the bone
frequently, suggesting that breast cancer cells express genes that
enable them to thrive within the bone environment. As BMPs are
critical regulators of bone homeostasis [275], and breast cancer
cells express all the components of theBMPpathway and areBMP
responsive, BMPs are poised to regulate breast cancer pathogen-
esis [276]. Recently decreased BMP-7 expression in primary
breast cancer specimens was associated with bone metastases,
while increasing BMP-7 levels in a bone metastasis mouse model
inhibited breast cancer metastasis to the bone [277]. In addition,
BMP-2 promotes the proliferation of breast cancer cells in vivo
[278], high levels of ALK6 are associated with increased tumor
grade, proliferation, and a poorer prognosis for patients [279],
while BMP-4 increases breast cancer cell invasiveness [280].
These studies suggest that the BMP axis promotes breast cancer
progression but inhibits metastasis of breast cancer to the bone.Table 2
Germ-line mutations in TGF-β superfamily members in human disease
Disease
Cardiovascular system Hereditary Hemorrhagic Telangiectasia
Loeys–Dietz syndrome
Familial thoracic aortic aneurysm syndrome
Primary pulmonary hypertension
Connective tissue Marfan syndrome
Sphrintzen–Goldberg syndrome
Furlong syndrome
Skeletal and muscular system Camurati–Englemann disease
Fibrodysplasia Ossificans Progressiva
Hunter–Thompson and Grebe-type chondrodyspla
Sclerosteosis
Van Buchem disease
Brachydactyly type C
Brachydactyly type A2
Symphalangism
Reproductive system Premature ovarian failure
Persistent Müllerian duct syndrome
Developmental disorders Situs Ambiguus
Cleft palate
Metabolic disorders Hereditary hemochromatosis
Juvenile hemochromatosis
Hereditary cancer Juvenile polyposis
Hereditary nonpolyposis colorectal cancer
Bannayan–Riley–Ruvalcaba syndrome
Cowden syndrome7.2. Colorectal cancer
TGF-β is a critical regulator of normal colonic epithelial
homeostasis. Loss of TGF-β responsiveness occurs frequently
during colon cancer progression, usually though mutational
inactivation of TGFBR2 or SMAD4 [253]. Colorectal cancers
can be divided based on their genetic stability, with about 12%
of colorectal cancers exhibiting microsatellite instability (MIS)
due to errors in mismatch repair. While some MIS(+) colorectal
cancers are due to HNPCC, most are sporadic. In either case,
MIS(+) tumors are more likely to have mutations in TGFBR2,
due to the polyadenine repeat sequence in the coding sequence
of the TGFBR2 gene [281]. Overall approximately 30% of
colorectal cancers exhibit mutations in TGFBR2. Mouse models
support a role for TβRII in colon cancer progression as crossing
APC null mice with mice lacking TβRII in their colonic epithe-
lium significantly increased the number of intestinal adenocar-
cinomas as compared to APC null mice mated to wild-type
TβRII expressing mice [282].
While the SMAD4 gene ismutated or deleted in about 16–25%
of colorectal cancers [281], SMAD2 is mutated in only about 6%
of colorectal cancers [283], and mutations in SMAD3 have not
been identified. However, Smad3 may also contribute to colon
carcinogenesis, as one murine model lacking Smad3 developed
metastatic colon adenocarcinomas by six months of age [283].
TGF-β signaling in the tumor microenvironment is also critical
for tumor progression. When SMAD4 is knocked out in T-cells,
there was a marked increase in the occurrence of gastrointes-
tinal tumors [284]. An important tumor suppressive function forSuperfamily signaling component
Antagonists Ligands Receptors Smads
ENG, ACVRL1 SMAD4
TGFBR1, TGFBR2
TGFBR1, TGFBR2
BMPR2 ACVRL1
FBN1 TGFBR1, TGFBR2
TGFBR2
TGFBR1
TGFB1
ACVR1
sia GDF5
SOST
Enhancer for SOST
GDF5
BMPR1B
NOGGIN GDF5
BMP15, INHA
MIS AMHR2
LEFTY1 NODAL
TGFB2, TGFB3
HJV
BMPR1A, ENG SMAD4
TGFBR1
BMPR1A
BMPR1A
Table 3
Alterations in TGF-β superfamily members in sporadic human disease
Disease Superfamily signaling component
Ligands Receptors Smads
Cardiovascular system Atherosclerosis Decreased TGF-β1 TGFBR2 mutations
Hypertension TGFB1 polymorphisms (increased TGF-β1 )
Dilated TGFB1 polymorphisms (increased TGF-β1 )
Cardiomyopathy BMP10 polymorphisms (increased BMP10 )
Pre-eclampsia Increased sEnd
Restenosis Increased TGF-β1 levels
Skeletal and
muscular system
Osteoporosis TGFB1 polymorphisms (increased TGF-β1 )
Cancer Breast cancer TGFB1 polymorphisms (increased TGF-β1 ) TGFBR1 polymorphisms; decreased
TβRIII, TβRII, TβRI; increased ALK6TGFB2 polymorphisms (increased TGF-β2 )
Increased BMP-4
Decreased BMP-7
Colon cancer TGFB1 polymorphisms (increased TGF-β1 )
increased BMP
TGFBR2 mutations SMAD2, SMAD4 mutations
Lung cancer TGFBR2 mutations, decreased TβRII SMAD2, SMAD3 mutations
Pancreatic cancer Increased TGF-β1, TGF-β2 TGFBR2 mutations, decreased TβRIII,
TβRII, TβRI
SMAD4 mutation
Prostate cancer TGFB1 polymorphisms (increased TGF-β1 )
increased GDF-15
Decreased TβRIII Increased Smad3,
Smad4 nuclear localization
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involved in prostaglandin synthesis, which is significantly in-
creased early in colon tumorigenesis, and has been shown in mice
to be required for tumor progression [285].
Recently a study characterized the risk of advanced colorectal
adenoma with TGFB1 polymorphisms. The genetic alterations
that resulted in increased serum levels of TGFB1 (TGFB1-509TT,
10Pro/Pro) were associated with a greater risk of advanced colo-
rectal cancer, especially in patients with multiple adenomas and
rectal adenoma [286].
There is much less known about the contribution of other
TGF-β superfamily members to colon cancer; however, there is
evidence for a role of BMPs in colon cancer progression. As
mentioned previously, loss of BMPR1A contributes to hereditary
colon cancer progression, BMPs are upregulated in colon cancer
[287], and BMPs can increase the invasiveness of colon cancer
cells in vitro [287,288]. Recently, BMPR2 was knocked out in
stromal cells of the colorectal mucosa in mice and this resulted in
hyperplasia throughout the colonic epithelium due to increased
proliferation and decreased apoptosis. These mice developed
polyps throughout the colon and experienced intestinal bleeding
[289]. This data supports a potential tumor suppressor role of
BMPRII in the tumor microenvironment.
7.3. Pancreatic cancer
TGF-β is a critical regulator of pancreatic cancer homeostasis
[290], and components of the TGF-β pathway are often the target
of disruption during pancreatic carcinogenesis. In a majority of
human pancreatic cancers and cell lines; mutations in TGFBR1
and TGFBR2 have been identified that alter protein and/ormRNA
levels [291–293]. In addition, SMAD4 is mutated in 50% of all
human pancreatic cancers, supporting an important tumor
suppressor role for the TGF-β pathway [294,295]. Mouse models
support the importance of altered TGF-β signaling in pancreaticcancer progression.KRAS is mutated in 90% of human pancreatic
cancers and is thought to initiate the events that promote tumor
progression. When one copy of SMAD4 is inactivated in mice
harboring this mutation, they develop mucinous cystic neoplasms
that progress to invasive ductal adenocarcinomas [296]. When
TGFBR2 is knocked out in mice with an active KRAS mutation,
100% of the mice develop aggressive pancreatic ductal adeno-
carcinoma [297]. In human patients, TGF-β1 and TGF-β2 levels
are high and this correlates with tumor growth and metastasis
[298,299]. Recently we determined that TβRIII mRNA and pro-
tein expression is reduced in pancreatic adenocarcinoma, and this
loss in expression correlates with increased tumor grade [300].
This loss of TβRIII expression occurs during epithelial to mesen-
chymal (EMT), a process inwhich non-motile polarized epithelial
cells acquire motility and invasiveness which contributes to
metastasis. The loss of TβRIII is required for the induction of
motility and invasiveness of pancreatic cancer cells, but not the
other aspects of EMT, such as decreases in E-cadherin or induc-
tion of Snail expression [300].
7.4. Lung cancer
Lung cancer is categorized into small cell lung cancer and
nonsmall cell lung cancer (NSCLC), which includes adenocarci-
noma, squamous cell carcinoma, large cell carcinoma, and giant
cell carcinoma [301]. TGF-β signaling critically regulates lung
development and homeostasis. In NSCLC, the progression of
premalignant bronchoepithelial lesions towards invasive carci-
noma is associated with a decrease in TβRII expression at the
mRNA and protein level [302–304]. A 16 bp microdeletion in
exon 4 of TGFBR2 has been identified in patients with giant and
large cell variants of nonsmall cell lung carcinoma. This mutation
results in a premature stop codon that produces a truncated
receptor that is expressed at the cell surface, which has a mutated
transmembrane domain and no kinase domain. Lung cancer cells
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growth inhibition and fibronectin synthesis [301]. Loss of TβRII
expression increases the invasiveness of lung cancer cells [304],
and this invasion is dependent on the activity of RANTES, a
chemokine that is secreted by inflammatory cells and tumor cells
[305]. TβRIII mRNA and protein expression are also frequently
reduced in NSCLC patients, with loss correlating with increased
tumor grade and disease progression [306]. This loss of TβRIII
expression results in increased migration, invasion, and ancho-
rage-independent growth in vitro and tumor growth in vivo,
supporting TβRIII as a tumor suppressor gene in NSCLC [306].
NSCLC patients also occasionally harbor mutations in SMAD4
and SMAD2, in 7% and 4% of cases, respectively. In contrast to
NSCLC, most small cell lung cancer patients become resistant to
TGF-β through loss of TβRII expression, through mechanisms
that remain to be determined [307].
The lungs are often the target of metastasis, especially by
breast cancer cells. There is also evidence for TGF-β in promoting
metastasis to the lungs; (1) administration of a TβRI kinase
inhibitor inhibited lung metastasis in an orthotopic xenograft
model of lungmetastasis and in an intracardiac injection model of
experimental lungmetastasis by the breast cancer cell line,MDA-
MB-435-F-L [308], and (2) TGF-β promotes expression of in-
flammatory chemoattractants and myeloid cell recruitment in the
lungs, which attract primary tumor cells to infiltrate the lungs
[309].
BMPs also have an emerging role in lung cancer. There is
aberrant expression of BMP-2 in 98% of human lung cancers,
and there are increased levels of phosphorylated Smad1/5, and
the BMP responsive gene, Id-1 in human lung tumors, sup-
porting increased BMP signaling in human lung cancer [310].
BMP-2 increases the growth of human lung cancer epithelial
cells both in vitro and in vivo in nude mice, [310], and it was
recently shown that BMP-2 induces the transformation of lung
cancer cells via activation of the PI(3)K/mTOR pathway [311].
Overall these data indicate that BMP signaling critically con-
tributes to lung cancer progression.
7.5. Prostate cancer
TGF-β is thought to critically regulate androgen-dependence
in the prostate and to contribute to the progression of prostate
cancer by promoting the resistance of prostate cancer cells to
inhibitory hormonal growth signals [312]. A polymorphism has
been identified in TGFB1 (C-509T) that increases its expression
and is associated with a two-fold greater risk for developing late
stage prostate cancer [313]. Numerous animal model studies
suggest that aberrant TGF-β signaling contributes to prostate
cancer progression including: (1) blocking TGF-β signaling by
expressing a dominant negative TβRII suppressed androgen-
independent growth of prostate tumor cells in nude mice [314];
(2) expression of a dominant negative TβRII in the prostate of
a prostate cancer mouse model increased metastasis [315];
(3) expression of wild-type TβRII in prostate cancer cells re-
duced their growth by inducing apoptosis [316]; and (4) ex-
pression of a dominant negative Smad3 abrogated the growth
and metastasis of prostate cancer cells in nude mice [317].In human patients, there is evidence for increased TGF-β
signaling in advanced prostate cancer including: (1) elevated
serum levels of TGF-β1 [318]; (2) a positive correlation between
TGF-β1 serum levels and Prostate Specific Antigen (PSA) levels,
a bio-marker associated with prostate cancer [319]; (3) increased
expression of Smad3 in prostate tumors [317]; and (4) nuclear
overexpression of Smad4 in prostatic tumor tissue [320].We have
recently demonstrated that loss of TβRIII expression is an im-
portant contributor to human prostate cancer progression. TβRIII
expression is reduced in prostatic tumor tissue and re-expression
of TβRIII in prostate cancer cells reduced their invasiveness and
growth in nude mice [321].
Several other TGF-β superfamily members have been impli-
cated in suppressing prostate cancer progression. GDF-15 has
been associated with early stages of prostate cancer; in a prostate
cancer mouse model, there is a significant increase in the levels
of GDF-15 during hyperplasia and prostatic intraepithelial
neoplasia development [322]. In addition, BMP-7 expression is
reduced in advanced prostate adenocarcinoma, and administra-
tion of BMP-7 to mice potently inhibits prostate cancer bone
metastasis [323].
8. Developmental disorders
Appropriate TGF-β superfamily signaling is critical during
embryogenesis from the initial stages of blastula formation,
during gastrulation, and throughout the multiple stages of organ
development. Misregulation of TGF-β superfamily signaling is
often lethal, as demonstrated by the embryonic lethal pheno-
types of knock-out mouse models of numerous TGF-β super-
family signaling components [67].
8.1. Cleft palate
Cleft Palate (CP) is one of the most common congenital
malformations, which can be associated with other diseases (see
Marfan syndrome and Loeys–Dietz sections). CP arises from
failure of the adherence of the two palatal shelves or from failure
of the medial edge epithelial cells of the palate to undergo
epithelial to mesenchymal transition (EMT), in which adherent
and non-motile medial edge epithelial cells acquire motility and
invasiveness [324]. EMT is associated with the loss of epithelial
markers including E-cadherin and cytokeratins, which are im-
portant in the maintenance of epithelial cell junctions, and gain of
mesenchymal markers including vimentin and N-cadherin. The
TGF-β pathway is an important regulator of EMT, as TGF-β
initiates and maintains EMT in many different systems in vitro
and in vivo [325]. CP is thought to arise from genetic and envi-
ronmental modifiers. Several polymorphisms have been identi-
fied in TGFB2 and TGFB3 that are associated with CP [326,327].
Although, there have not been many polymorphisms in
TGFB1 identified in CP patients and the TGF-β signaling
mechanisms are still being defined, mouse models indicate an
essential role for TGF-β in proper palate development. When
TGFBR1 is knocked out in embryonic ectoderm and neural
crest lineages in mice, they develop CP [328]. TGFB3 knock-
out mice also exhibit CP with complete penetrance [329], and
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overexpressing Smad2 [330].
8.2. Situs Inversus and Situs Ambiguus
Humans have conserved left–right visceral asymmetries, for
example the left-sided heart and spleen and right-sided liver and
gall bladder. When there are errors in establishing this asym-
metry, serious human diseases can arise such as Situs Inversus
(SI), which is a mirror-image reversal of normal symmetry or
Situs Ambiguus (SA), abnormal placement of certain organs. SA
is usually more severe as it is associated with fatal cardiac
malformations that often lead to death, and affects the digestive
system including the liver, biliary tract, and bowel. Chromosome
abnormalities, maternal diabetes, and retinoic acid exposure
during pregnancy have all been implicated in contributing to SI
and SA. However, recently several TGF-β superfamilymembers
have been shown to directly regulate left–right axis determina-
tion, including nodal [331]. Nodal is normally expressed on the
left side of embryos during development, and in a mouse model
that exhibits mirror-image reversal of normal symmetry, nodal is
expressed on the right-side [332]. Mice deficient in nodal exhibit
left–right malformations including abnormal placement of the
heart, lungs, and digestive organs [333]. These potent effects of
Nodal on left–right axis determination in mice prompted
sequencing analysis of the NODAL gene in human patients
with SA. A mutation in the prodomain of NODAL (R183Q) was
identified in a patient with SA, as well as in her mother who did
not exhibit SA [334].
Similarly to Nodal, Lefty-1 and Lefty-2 are also expressed
asymmetrically during development [335,336]; they are ex-
pressed only in the left half of gastrulatingmouse embryos, and in
mice that exhibit SI, there is an inversion of Lefty-1 expression
[335,336]. Lefty-1 knock-out mice exhibit left-sided morphology
of both lungs, cardiacmalformations, abnormalities of the inferior
vena cava, and there are alterations in the asymmetric expression
of Lefty-2 and Nodal, suggesting that Lefty-1 regulates the
expression of these TGF-β superfamily members [337]. Muta-
tions inLEFTY1 have been identified in human patients with left–
right malformations. In 112 sporadic cases of left–right axis
malformations, 2 mutations were found in LEFTY1. Both muta-
tions affect the cysteine knot, which mediates receptor binding.
One mutation introduces a premature stop codon, producing a
truncated protein, and the other is a single base change that affects
a conserved serine. The patients with these two mutations had
similar clinicalmanifestations including left ventricle hyperplasia,
atrioventricular canal defect, left-sided superior vena cavae,
and left-sided lungs, which is similar to the phenotype of the
LEFTY1−/− mouse. These mutations were not identified in the
affected individual's parents, supporting the somatic nature of
these mutations [338].
GDF-1 has also been implicated in left–right patterning in
mice. Unlike Nodal and Lefty-1, GDF-1 is expressed throughout
the embryo at first, and then is localized to the primitive node,
ventral neural tube, and lateral platemesoderm.Mice deficient in
GDF1 exhibit SA, and have misexpression of Lefty-1, Lefty-2,
and Nodal, suggesting that GDF-1 may be upstream of theseother TGF-β superfamily members [339]. No mutations in
GDF1 have been identified thus far in humans with SA or SI.
9. Emerging role for TGF-β superfamily members in other
human diseases
This review has focused on diseases in which TGF-β super-
family signaling has been extensively studied and importantly
(Fig. 3, Tables 2 and 3), where alterations in TGF-β superfamily
signaling components have been directly linked to human disease
(Table 2). However, TGF-β superfamily members are contin-
ually being linked to other diseases. For example, alterations in
TGF-β1 expression have been observed in several neurological
disorders including: autism [340], schizophrenia [341], Parkin-
son's disease [342], multiple sclerosis [343], and Alzheimer's
disease [344], while activin expression is altered in Huntington's
and Parkinson's disease [345]. Mouse models have been devel-
oped for many of these diseases, so it will be beneficial to
determine how targeting TGF-β superfamily members affects the
progression of these diseases. Recently, TGFB1 polymorphisms
were identified in patients with otosclerosis [346], a progressive
loss of hearing that results from increased remodeling of the otic
capsule, as well as in psoriases [347], biliary cirrhosis [348], and
childhood asthma [349]. Thus the range of diseases in which
TGF-β superfamily members have a role will likely continue to
grow.
Other TGF-β superfamilymembers, particularly the BMPs are
continually being implicated in human diseases. Recently, BMPs
were implicated in iron metabolic disorders, including anemia
and hemochromatosis (iron overload). Hemojuvelin is a BMP co-
receptor that participates in the positive regulation of levels of
the liver hormone hepcidin, which regulates iron balance by
decreasing the cell surface expression of the iron exporter
ferroportin and thus decreases iron absorption in the stomach
[350]. Mutations in BMP family members have been identified in
patients with hemochromatosis including BMP2, BMP4, and
HJV [351]. Modulating the BMP pathway in patients with these
disorders has recently been proposed, as administering BMP-2 to
mice increases hepcidin expression and decreases serum iron
levels, while administering soluble hemojuvelin has a reciprocal
effect [352].
10. TGF-β superfamily members as diagnostic, prognostic
or predictive markers
Since specific alterations in TGF-β superfamily members
contribute to numerous human diseases (Table 2, Table 3 and
Fig. 3), these alterations could serve as valuable diagnostic,
prognostic, or predictive markers. In particular, assessing ligand
levels or levels of soluble TGF-β superfamily receptors in
serum is useful due to the ease and accessibility of these speci-
mens, and ability to monitor over time.
Several TGF-β superfamily signaling components have been
assessed as prognostic markers for several cardiovascular
diseases. Recently high serum levels of soluble endoglin during
the second trimester of pregnancy were determined to be
predictive of developing pre-eclampsia [118]. This information
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patients need closer supervision and how aggressively to treat
patients at risk for pre-eclampsia. In addition, in patients with
coronary artery disease, high levels of TGF-β1 in the blood are
significantly associated with increased patient survival, with
fewer coronary events and need for interventions [353]. In
contrast, after angioplasty, there is a greater risk of developing
restenosis in those patients that have higher levels of TGF-β1 in
their blood 15 min, 24 h, and 2 weeks after the procedure was
performed [354], suggesting that these patients would benefit
from additional interventions to prevent restenosis.
Since TGF-β exerts potent tumor promoting activity later in
tumorigenesis, levels of TGF-β signaling components have fre-
quently been assessed as potential prognostic markers in several
cancer types. Increased serum levels of TGF-β1 has been impli-
cated as a marker of advanced disease and poor prognosis in
multiple cancers including esophageal adenocarcinoma [355],
gastric carcinoma [356], colorectal cancer [357], pancreatic
cancer [358], hepatocellular cancer [359], and breast cancer [360].
Decreased levels of TGF-β receptors within the tumor cells have
also been associated with poor outcome including: (1) reduced
TβRII expression is associated with increased lymph node meta-
stasis and reduced survival of colon cancer patients [361];
(2) reduced expression of TβRI and TβRII is associated with theFig. 3. Contribution of TGF-β superfamily signaling to human disease. The TG
development into adulthood. TGF-β superfamily signaling is tightly regulated at al
surface, and the levels of the downstream transcription factors that will ultimately dict
is altered, either through germ-line or somatic mutation, the pathway no longer effecti
diseases are associated with alterations in each level of the TGF-β superfamily signpathologic stage, metastasis, and decreased survival of esopha-
geal cancer patients [361]; (3) reduced expression of TβRII is
associated with the progression of premalignant lung lesions to
carcinoma in situ [302]; and (4) reduced expression of TβRIII is
associated with disease progression and a poorer prognosis for
breast and prostate cancer patients [272,321]. Measuring levels of
TGF-β superfamily downstream signaling effectors has also been
proposed as a prognostic marker as loss of phosphorylated
Smad2/3 expression is associated with a shorter disease-free
survival in breast cancer patients [362], patients with gastric
tumors with high Smad4 expression and low Smad7 expression
have higher survival rates [363], and loss of Smad2 and Smad4
expression in colon tumors is associated with advanced disease
including lymph nodemetastasis and a shorter survival rate [364].
These studies suggest that profiling the TGF-β signaling pathway
may aid in defining an appropriate treatment approach for
individual patients.
Other TGF-β superfamily members have been assessed as
prognostic markers in various tumor types including: (1) the
promoter of BMP6 is hypermethylated, resulting in decreased
BMP-6 expression, in aggressive diffuse large B cell lymphoma
and this is associated with reduced survival [365]; (2) BMP-7
expression is increased in malignant melanomas and their me-
tastases, and this correlates with shorter tumor recurrence [366];F-β superfamily regulates many critical physiological processes throughout
l levels, from the availability of ligand, to the amount of receptors on the cell
ate the outcome of TGF-β superfamily signaling. When any level of the pathway
vely regulates physiological processes, and human diseases arise. Indeed, human
aling pathway, as demonstrated here.
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the Gleason score in prostate cancer patients and is associated
with reduced disease-free survival [367].
TGF-β superfamily receptors have also been used to
facilitate imaging of solid tumors. Endoglin is overexpressed
on endothelial cells associated with tumor induced angiogenesis
[368]. Accordingly, a radioactively labeled-antibody directed to
endoglin has been used to visualize solid tumors that were not
detected by more conventional means in a canine model of
breast cancer [369], suggesting that this might serve as a
sensitive diagnostic marker of solid tumors.
11. Targeting TGF-β superfamily members therapeutically
As with any signal transduction pathway involved in human
disease, there are a myriad of methods for targeting the pathway.
In addition, as either increased or decreased activity of these
pathways has been implicated in the pathogenesis of different
human diseases (Tables 2 and 3), methods for both increasing
and decreasing signaling through these pathways are required.
In terms of diseases with either decreased TGF-β superfamily
signaling including HHT and hereditary cancer syndromes, or
where elevating TGF-β superfamily signaling would be bene-
ficial, including atherosclerotic heart disease; several mechanisms
for elevating TGF-β signaling are available including: (1) admin-
istering the ligand directly; (2) using agonists; (3) increasing
expression of the appropriate receptors; or (4) decreasing the
expression of signaling antagonists. Recently, the efficacy of the
anti-fibrinolytic drug Tranexamic Acid (TA) was assessed in
preventing recurrent nosebleeds in HHT patients. TA effectively
reduced the frequency and severity of nosebleeds in patients.
Mechanistically, TA increased ALK1 and endoglin mRNA and
protein expression in primary endothelial cells and increased
ALK1 and endoglin mediated signaling as measured using tran-
scriptional reporter assays, migration, and tube formation assays,
suggesting that TA functions to restore TGF-β superfamily
signaling by increasing receptor-mediated signaling in this disease
[370]. Another example of a potential stimulator of TGF-β
signaling is the statin class of drugs, used to suppress cholesterol
levels and decrease risk of cardiovascular disease. Recently, it was
demonstrated that cholesterol decreases the binding of TGF-β to
ALK5 and TβRII, and effectively suppresses TGF-β signaling;
whereas, statins, drugs that inhibit cholesterol synthesis, increase
TGF-β responsiveness. Therefore, patients with atherosclerosis
that take statins will have decreased serum cholesterol levels as
well as the added benefit of increased TGF-β signaling [371].
These examples highlight the importance of using drugs that
stimulate TGF-β signaling to treat diseases that manifest from
insufficient TGF-β signaling.
Alternatively, TGF-β superfamily ligands could be adminis-
tered directly to patients. In an atherosclerosis mouse model,
overexpression of TGF-β1 by viral delivery suppressed athero-
sclerosis [129]. In addition, administering myostatin directly to
patients with Duchenne muscular dystrophy may be a useful
therapeutic strategy to rebuild muscle mass. Due to BMP's potent
stimulation of bone formation, most therapeutic interventions
thus far have targeted this role; BMP-2 has been administeredlocally to the upper or lower jaw of patients receiving dental
implants to assess whether it can stimulate bone formation [372],
and at fracture sites to determine if it can accelerate healing [373].
In terms of diseases with increased TGF-β superfamily sig-
naling including Camurati–Engelmann disease, Fibrodysplasia
Ossificans Progressiva, Marfan syndrome, and most advanced
cancers, decreasing TGF-β superfamily signaling would be
beneficial. There are many ways to inhibit TGF-β superfamily
signaling including; (1) neutralizing antibodies; (2) soluble recep-
tors; (3) natural or synthetic antagonists; (4) antisense nucleotides
that reduce expression; and (5) small molecule inhibitors of the
receptor serine/threonine kinases. Neutralizing antibodies are
frequently the therapeutic method of choice for inhibiting TGF-β
superfamily signaling since they are particularly effective; they
bind directly to the ligand and prevent it from binding to its
receptor, effectively shutting down superfamily signaling.
Numerous clinical trials have been performed with neutralizing
antibodies, especially in fibrotic diseases including: (1) a TGF-β2
neutralizing antibody (lerdelimumab) effectively decreased the
amount of scarring after glaucoma surgery [374]; (2) a TGF-β1
neutralizing antibody (metelimumab) is being administered to
patients with systemic sclerosis, which causes scarring in skin and
internal organs [375]; and (3) a pan-TGF-β (GC-1008) neutraliz-
ing antibody is currently being administered to patients with
idiopathic pulmonary fibrosis [376]. TGF-β neutralizing anti-
bodies have frequently been assessed as anti-cancer therapeutics.
The efficacy of the GC-1008 neutralizing antibody is also being
assessed in patients with advanced renal carcinoma andmalignant
melanoma [377]. In mice, a TGF-β neutralizing antibody sup-
pressed radiation-induced acceleration of metastatic breast cancer
progression [378].
Soluble TGF-β superfamily receptors have also been utilized
as therapeutic agents. Similar to neutralizing antibodies, they
abrogate signaling at the ligand level by binding ligand and
preventing it from binding to cell surface receptors. For example,
soluble TβRIII has demonstrated efficacy against renal damage
progression associated with diabetes in mice [379], and inhibits
the growth and angiogenesis of human colon and breast cancer
cells in vivo [380]. Soluble TβRII has similar anti-cancer effects
in mice, it suppresses the growth and metastasis of pancreatic
cancer cells [381] and inhibits breast cancer cell growth,
migration, invasion, and metastasis [382]. Whether this strategy
will work in humans warrants further investigation.
An alternative strategy is to identify and/or develop antag-
onists of TGF-β superfamily signaling. In Marfan syndrome
(MS), there is increased TGF-β activity due to insufficient
binding by fibrillin [see MS section], suggesting use of inhib-
itors of TGF-β signaling in this disease. In fibrillin-1 deficient
mice, a murine model of MS, the angiotensin receptor blocker
losartan, which should antagonize TGF-β1 signaling through
inhibition of the renin–angiotensin system (see Fig. 2), pre-
vented the development and progression of aortic aneurysms by
reducing aortic wall thickness and aortic root growth, and im-
proved aortic wall architecture [383]. This effect was attributed
to suppression of TGF-β signaling as losartan reduced levels of
phosphorylated Smad2 levels in the aortic walls and adminis-
tration of a TGF-β neutralizing antibody was able to mimic the
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rescued the alveolar septation defect phenotype, which com-
monly occurs in human MS patients [383]. Another clinical
manifestation of MS is myopathy, which is also thought to be a
result of increased TGF-β signaling in muscle fibers. Similarly,
losartan treatment of fibrillin-1 deficient mice also resulted in
regeneration and restoration of normal muscle architecture,
while reducing levels of phosphorylated Smad2 and 3, and these
effects could also be achieved by administration of a TGF-β
neutralizing antibody [384]. Interestingly, these effects may not
be limited to MS-associated myopathy as losartan has similar
effects on muscle architecture and regeneration in the MDX
Duchenne muscular dystrophy (DMD) mouse model (arises
frommutations in dystrophin, see DMD section) [384]. Losartan
may prove to be a valuable tool for treatingMS and DMD, with a
current study evaluating whether losartan treatment reduces
aortic root enlargement in MS patients [385].
Recently, Burmester et al. screened a chemical library and
identified 5 small molecule antagonists that specifically abro-
gate the ability of TGF-β to bind to its receptor and attenuate
TGF-β mediated growth inhibition [386]. It will be interesting
to see if these compounds are also effective in mouse models of
TGF-β superfamily diseases, especially in MS and DMD where
increased TGF-β signaling contributes to disease pathology.
Using antisense oligonucleotides to reduce expression of
TGF-β superfamily members is a relatively new therapeutic tool
that has been successful in treating cancer. A TGF-β2-specific
antisense oligodeoxynucleotide (AP 12009) prolonged the sur-
vival of high grade glioma patients with two patients experiencing
complete remission [387], and it is now being considered for use
in other TGF-β2 overexpressing tumors. A TGF-β2 antisense
transgene also prolonged the survival of patients with NSCLC
[388].
Small molecule inhibitors have been developed to block
TGF-β superfamily signaling at the receptor level. A small
molecule inhibitor (Ly573636) of TβRI/ALK5 kinase activity is
currently being assessed in patients with malignant melanoma
[389], soft tissue sarcoma [390], NSCLC [391], and ovarian
cancer [392]. ALK5 inhibitors have demonstrated efficacy in
mouse models including reduction of the growth of mesothe-
lioma, and they reduce the rate of recurrence after surgical
resection [393]. Development of ALK2 inhibitors would be
useful for treatment of Fibrodysplasia Ossificans Progressiva,
for which there are currently no cures or effective treatments.
The therapeutic benefit of specifically inhibiting TGF-β super-
family receptors in diseases other than cancer is just beginning
to be realized.
12. Concluding remarks
As we have described, the TGF-β superfamily regulates a
plethora of vital functions throughout embryonic development
and adulthood. There is tight regulation at all levels of TGF-β
superfamily signaling, and when components are altered by
germ-line or sporadic alterations, human diseases frequently
arise (Fig. 3). Understanding the molecular basis of these TGF-β
superfamily alterations is critical to make a correct diagnosis,and to design effective therapies based on the genetic alterations
in each individual patient. For many of the diseases with altered
TGF-β superfamily signaling, there are no effective treatments
available and patients will eventually die from progressive
complications. Therefore, further work is necessary to elucidate
precisely how TGF-β superfamily signaling is altered in each
disease, and to define effective strategies for targeting TGF-β
superfamily signaling pathways.
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